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Anemia of pregnancy remains highly prevalent in Senegal despite the national 
iron/folic acid (IFA) supplementation program, which consists of providing 
prescriptions to purchase IFA to women during prenatal visits.  The purpose of this 
study was to provide a framework for recommendations to improve the effectiveness 
of the program.  We determined the prevalence and risk factors of anemia in a cohort 
of 480 pregnant women at 6 prenatal health centers in Dakar; we compared 
compliance after 20 weeks of supplementation between women who received 
prescriptions at 3 control centers and those who received free IFA at 3 intervention 
centers; and we assessed the factors that influenced high and low compliance in both 
groups.  Overall, 39% of women were anemic and 71% were iron deficient (ID).  
Twelve percent were infected with P. falciparum; 21% had intestinal helminthes, and 
6.5% had Hb AS.  Women consumed foods containing iron absorption inhibitors at 
high frequency.  ID > quadrupled the risk of anemia; malaria and Hb AS also 
significantly increased the risk for anemia.  Compliance was 48% and 86% in the 
control and intervention groups, respectively (P<.001).  Anemia prevalence was 62% 
among controls versus 31% among interventions (P<.01); ID prevalence was 84% 
and 57% in the control and intervention groups, respectively (P<.01).   Women with 
high compliance were motivated by 1) the perception of improved health upon taking 
the tablets, 2) the insistence by midwives that they take them, and 3) the mention that 
the tablets would improve health.  Women with low compliance indicated 1) 
experiencing side effects that they associated with the tablets, 2) misunderstanding 
that they needed to continue taking the tablets throughout pregnancy, and 3) 
forgetfulness.  Our findings indicate that for effective control of anemia in Senegal, 
iron supplementation is needed in addition to educating women about better food 
choices.  Antimalarial chemoprophylaxis and helminthes screening should be made 
available to all women.  In addition, increasing access to IFA and educating women 
about the health benefits of the tablets can dramatically increase compliance and 
therefore improve iron status and decrease the incidence of anemia.   
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Chapter 1: Introduction 
 
It was in the 1970’s that iron deficiency was identified as the leading single-
nutrient deficiency worldwide.  Today, at the dawn of the 21st century, iron deficiency 
still affects more than 2 billion people around the world despite the numerous and 
extensive strategies used to decrease its prevalence (1, 2).   
The pathogenesis of iron deficiency can be divided in three stages.  The earliest 
stage involves the loss of iron stores without a decrease in the iron supply to red blood 
cells (RBC).  Continued deficiency leads to iron-deficient erythropoiesis (decline in the 
iron supply to RBCs), which nevertheless does not affect circulating hemoglobin (Hb) 
levels.  A continued loss of iron or lack of replenishment of iron stores results in the third 
and final stage, which is termed iron deficiency anemia (3).  Anemia can therefore be 
defined as a state in which the number of RBCs, the quantity of Hb, or the volume of 
packed red cells (hematocrit) in blood is reduced below normal levels (4).   
The World Health Organization estimates that about 1.3 billion individuals 
worldwide suffer from anemia, which is 22% of the world’s population and 3.5 billion 
people have iron deficiency (5).  Most of these individuals reside in the developing 
countries of Sub-Saharan Africa and South East Asia and most of them are pregnant 
women and children (1, 2, 6).  In Western Africa, it is estimated that at least 47% of 
pregnant women are anemic (6).  Pregnant women are particularly susceptible to iron 
deficiency and eventually anemia partly because of the normal physiological changes that 
occur during pregnancy.  These changes include a dramatic maternal red cell expansion 
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around 20 to 25 weeks of gestation and fetal erythropoiesis (which directs the placenta to 
accumulate iron) during the 3rd trimester of gestation such that the expectant mother 
needs up to more than 1000 mg of iron in order to cover the cost of pregnancy (7, 8).  In 
the developing world, this increased need for iron can rarely be met through dietary 
adjustments alone because of low iron intake, low bioavailability of iron in foods 
consumed, and women entering pregnancy with low iron stores (6, 9).   
Even though iron deficiency is the most common cause of nutritional anemia 
among pregnant women, it is not the only cause, especially in developing countries.  
Multiple causes of anemia often coexist among women in Sub-Saharan Africa.  These 
causes include deficiencies in other hematopoeitic nutrients such as folate and vitamin 
B12 (10-13), deficiencies in vitamin A (14), genetic diseases causing hemolysis (sickle 
cell and thalassemias) (15), concurrent infections and inflammations (16-18), Malaria 
(19), and parasitic infections that cause gastrointestinal blood loss: Acylostoma 
duodenale, Necator americanus, Trichuris trichiria, Ascaris lumbricoides, and 
Schistosomes (20-22).  
Anemia during pregnancy and specifically iron deficiency anemia during the first 
and second trimesters of gestation increases the risk of low birth weight (LBW) and 
preterm delivery, which are the strongest predictors of perinatal mortality (23-24).      
Iron supplementation of pregnant women who visit prenatal care clinics is one of 
the most widely used strategies to combat anemia and iron deficiency anemia in Sub-
Saharan Africa (25).   However, although clinical trials have repeatedly shown that iron 
supplementation increases pregnant women’s iron stores and Hb concentrations, 
community and population-based public health iron supplementation programs, including 
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the ones implemented in antenatal clinics, have failed to improve iron status and decrease 
the prevalence of anemia (26).  This failure may be due to failures in the distribution of 
supplements to antenatal clinics, to a lack of resources or availability of supplements, to 
poor training of the health care staff in understanding the importance of the supplements 
and conveying it to patients, and to the fact that iron supplements do not treat the 
underlying causes of anemia other than iron deficiency.  In addition, compliance of 
pregnant women with the regimen of supplements is relatively low (27) because of 
limited resources to purchase the supplements, the gastrointestinal side effects that may 
be associated with iron supplements, and because the health care staff does not convey 
the importance of the supplements to women; community attitudes may also influence 
supplements consumption (27-28).  
As is typical of most countries in Sub-Saharan Africa, the prevalence of anemia 
among pregnant women in Senegal is high.  Unfortunately, there is a paucity of data on 
the prevalence and major causes of anemia in that country.  No national survey has been 
conducted to gather this data.  In the year 2000, World Vision Senegal performed an end 
of project survey in four rural districts in which they found that 55% (n = 278) of 
pregnant women were anemic (29).  Ndiaye et al (30) found that 45% (n = 79) of 
pregnant women in a hospital in Dakar, the capital city of Senegal, were anemic.  An 
unpublished paper (31) reported that 64% (n = 309) of low-income women at an antenatal 
care clinic in Dakar were anemic.   
The high fertility rate in Senegal accounts for 450,000 births yearly; the 
prevalence of low birth weight in 15%; maternal and infant mortality rates are high at 
560/100,000 and 58/1,000 live births, respectively.  In order to combat anemia, in the 
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1990’s the Senegalese Ministry of Health instituted a program of universal prescription of 
iron/folic acid tablets for all pregnant women attending health centers for prenatal care 
around the country.  No data are available to indicate whether this strategy has been 
effective; however, given what we know of the low compliance associated with 
community-based iron supplementation programs of this type elsewhere, we suspected 
that effectiveness may need improvement.     
The main objective of this study was to assess the effectiveness of the Senegalese 
supplementation program and to provide a framework for recommendations for 
improvement, if necessary.  We assessed the prevalence and major risk factors for anemia 
in a cohort of pregnant women attending health centers for prenatal care in order to 
evaluate the efficacy of iron/folic acid tablets alone in raising Hb concentration when 
causes of anemia other than iron deficiency may be prevalent in this population.  We then 
determined compliance with supplementation and compared it with that of women who 
received iron/folic acid tablets free of charge during the prenatal visit.  We hypothesized 
that giving women iron/folic acid tablets during the prenatal visit rather than merely 
prescribing the tablets for purchase would eliminate some of the known barriers to 
program success.  The net effect would be an increase in compliance and therefore 
improved iron status, and decreased incidence and prevalence of anemia among pregnant 
women.  Lastly, we determined the factors that influence compliance in this population 
because understanding these factors can be the basis of recommendations to improve 
patient care and counseling. 
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Chapter 2: Review of Selected Topics in the Literature 
 
1.Causes of anemia
1.1 Iron deficiency 
The major cause of anemia around the world, across groups and among pregnant women 
is iron deficiency.  Indeed, the World Health Organization (WHO) estimates that around 
3.5 billion individuals suffer from iron deficiency (5) and that nutritional deficiency due 
to the low bioavailability of dietary iron accounts for more than 50% of the cases (32-33). 
 
The role of iron in the human body 
Iron is an essential mineral in the metabolism of all living organisms.  The most 
important iron-containing compounds in the body are the heme proteins hemoglobin 
(Hb), myoglobin (Mb), and cytochromes, which have an iron-protoporphyrin prosthetic 
group.  Iron is bound at the center of the heme group (Figure 1), which is the site of 
oxygen uptake by Hb and Mb.  In turn, Hb plays an important role in transferring oxygen 
from the lungs to tissues, while the primary function of myoglobin is to transport and 
store oxygen within muscles.  Cytochromes are critical to respiration and energy 
metabolism through their role in mitochondrial electron transport.  Thus, iron plays 
central roles in energy metabolism and electron transfer (34).   
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Total body iron averages 4.0 g for men and 2.5 g for women.  Seventy five 
percent of this iron is in the functional form mostly as Hb in circulating RBCs and 15% 
as Mb.  The remaining 10% of body iron is in storage form in the liver, the 
reticuloendothelial cells, and bone marrow; storage iron exists in the form of two 
proteins, ferritin and hemosiderin.  (35). 
 
Figure 1: The chemical structure of heme 
 
Iron digestion and absorption 
Iron bioavailability from foods varies widely.  It is greatest from mammalian 
meat, less from poultry or fish, and least from liver, eggs, milk, and foods of plant origin 
such as legumes (36).  This difference in absorbability of iron is related to the difference 
between heme and non-heme iron, which form different iron pools in the body.  Non-
heme iron consists mostly of iron salts; it is found mainly in plants, dairy products, and 
iron-fortified foods.  More than 85% of the human diet consists of this form of iron (37).  
Heme iron is mostly found in Hb in meat, poultry, and fish.  Although heme iron is less 
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frequent in our diet than non-heme iron, the former is 2 to 3 times better absorbed than 
the latter (34).   
In meats of mammalian origin, iron in the ferric form (Fe 3+) is complexed with 
the heme groups of Hb and Mb.  Prior to absorption, the heme group is hydrolyzed from 
the globin portion of Hb and/or Mb by proteases in the stomach.  The acidity in the 
stomach reduces Fe 3+ to the ferrous form (Fe 2+), which dissociates from ligands more 
readily than Fe 3+. In the small intestine, further hydrolysis of the heme complex by 
proteases occurs and because of the alkaline environment, heme is readily absorbed in the 
duodenum and upper jejunum (38).  Within the mucosal cell, heme oxygenase liberates 
iron from the protoporphyrin ring of heme.  Iron is then transferred successively to the 
cytosolic proteins mobilferrin and paraferritin.  It is then transported to the serosal surface 
of the cell and enters circulation via the basolateral transporter known as ferroportin.  As 
it enters the blood, iron is oxidized by ceruloplasmin to Fe 3+ and then binds to 
transferrin (38).   
The digestion and absorption of non-heme iron differs from that of heme iron, 
which accounts for the difference in bioavailability.  Stomach secretions and hydrochloric 
acid that release non-heme iron from food components are thought to delay or prevent its 
reduction to the ferrous state; this means that iron dissociates less readily from its ligands 
and is therefore less readily absorbed.  Non-heme iron is taken up by one or more 
proteins of the luminal surface of the mucosal epithelium of the duodenum, including a 
transporter protein called divalent metal transporter 1 (DMT1) which facilitates transfer 
of iron across the intestinal epithelial cells (38).  Once inside the cell, Fe 3+ is reduced to 
Fe 2+ and absorption continues as described above.  Non-heme iron absorption can be 
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enhanced or hindered by food components ingested in the same meal.  Some chelators 
that increase absorption are ascorbic acid and other undefined factors contained in meat, 
fish, and poultry.  Non-heme iron absorption from a meal containing meat, fish, or 
poultry is about 4 times greater than that from a meal containing equivalent portions of 
milk, cheese, or eggs (34).  Some chelators that decrease absorption are tannins 
(contained in tea), phosvitin (contained in egg yolk), calcium and phosphate salts, and 
phytates in cereals (39-41).  Diets poor in heme iron and rich in iron absorption inhibitors 
have been documented all over sub-Saharan Africa (42-46).  The staples in Senegal are 
white rice and millet, which are high in phytates.  The Senegalese diet also includes a 
high consumption of green and black tea. 
 
Iron transport and metabolism 
Regardless of which form of iron is ingested, once absorbed, iron either remains 
in the mucosal cells for intestinal use or is bound by the glycoprotein transferrin for 
transport through the bloodstream to other body tissues (under normal conditions, 
transferrin binding sites are about 20 to 45% saturated with iron).  Most of the absorbed 
iron is transported to the bone marrow where Hb is formed in RBCs and later released 
into circulating blood.  RBCs have a life span of 120 days; to replace each 1/120 of 
erythrocytes, the daily iron turnover for an adult is about 20 mg.  Most of the iron from 
hemolysis is recaptured for the synthesis of Hb (34).  A smaller portion of iron enters iron 
stores as ferritin and hemosiderin in many organs, as myoglobin in the muscle cells, and 
as iron in cytochromes and cytochrome oxidase.  An even smaller portion of iron remains 
bound to transferrin (34). 
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Daily external losses of iron are very limited in healthy individuals 
[gastrointestinal blood loss (Hb): 0.35 mg; gastrointestinal mucosal loss (ferritin): 0.10 
mg; biliary loss: 0.20 mg; urinary loss: 0.08 mg; and skin loss: 0.20 mg]; thus, iron 
balance is maintained primarily through the regulation of iron absorption.   Healthy 
individuals absorb about 5 to 10% of dietary iron whereas individuals who are iron 
deficient absorb 10 to 50% of dietary iron (34).  
 
The pathogenesis of iron deficiency 
When dietary iron intake is inadequate or when the diet is high in non-heme iron 
and iron absorption inhibitors over a significant period of time, the process of iron 
deficiency begins with depletion of iron stores and impaired iron supply to various 
tissues.  During this phase of deficiency, the continuous supply of iron for erythropoiesis 
is adequate but no iron reserves exist to cover short-term needs.  Generally, no clinical 
symptoms are noted at this point.  If iron deficiency persists, the second stage of 
physiological iron deficiency ensues.  This stage is characterized by an impairment of 
erythropoiesis with little if any effect on circulating red blood cells.  Some clinical 
symptoms may be seen in this stage.  The third and last stage of iron deficiency, when 
left untreated, is anemia where the impairment of erythropoiesis is so severe that the 
number of RBCs is reduced, Hb concentration, and hematocrit concentration fall below 
normal levels.  The degree of anemia can range from mild to severe (Hb <70 g/L) to very 
severe (Hb <40 g/L).  Mild anemia can have very few health consequences, especially in 
sedentary individuals, because compensatory mechanisms maintain oxygen supply to the 
tissues (47).  Clinical symptoms associated with mild to severe anemia include fatigue, 
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decreased work capacity (48), behavior and cognitive impairment in children (49-50), an 
impaired capacity to maintain body temperature in a cold environment (34), impaired 
immunity and resistance to infections, and adverse perinatal outcomes in pregnancy (23). 
 
Assessment of iron status 
Iron status can be measured using hematological and biochemical indices. Each 
iron status index reflects changes in different body iron compartments and is affected at 
different levels of iron depletion.  Serum ferritin (SF) is directly proportional to body iron 
stores in normal individuals (51).  Quantitative phlebotomy studies indicate that 1 µg/L 
SF is equivalent to 8-10 mg of stored iron for an average-sized adult (34).  SF is 
considered the most specific test for iron deficiency because very low levels of the 
protein are almost always indicative of low iron stores.  Enzyme-linked immunosorbent 
assay (ELISA) with colorimetric fluorescent or chemoluminescent end points is widely 
used to measure SF (52).  The SF cutoff commonly used to identify low iron stores is <15 
µg/L for adults.  There is however a caveat for the use of SF as an indicator: SF is an 
acute phase reactant, which means that in individuals with acute or chronic 
inflammations or diseases that cause tissue destruction (acute phase), SF is elevated.  The 
SF measurement under these circumstances would yield false negatives for iron 
deficiency because levels can reach >20 µg/L even in the presence of advanced iron 
deficiency (53).  The acute phase response is a short-term metabolic change characterized 
by increased plasma concentrations of certain proteins, such as C-reactive protein (CRP) 
[CRP >190 nmol/L is considered elevated] and haptoglobin, and decreased 
concentrations of other proteins, such as albumin and retinol binding protein.  The 
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inflammatory response may last for several days or several weeks and months, in which 
case it is termed “chronic inflammation”.  Acute and chronic infections/inflammations 
are common in West Africa (e.g. malaria) and complicate the diagnosis of iron deficiency 
using SF.  However, SF has been shown to be a useful indicator when the cutoff is raised 
to <30 µg/L for pregnant women in areas where infection is prevalent (10, 54).  In a 
research setting, it is also advisable to measure SF and an acute phase protein (e.g. CRP) 
simultaneously in order to be able to control for the potential confounding effect of the 
acute phase response in the data analysis. 
Another measure of iron status is Erythrocyte protoporphyrin (EP), which is the 
precursor of Hb: the heterocyclic ring system of heme is a porphyrin derivative known as 
protoporphyrin, which has a centrally bound iron atom.  When there is insufficient iron 
available to combine with the ring to form heme during erythropoiesis or when too much 
lead is present and interferes with the process, there is an accumulation of protoporphyrin 
in RBCs (34).  The EP test was originally used to detect lead poisoning in children, but 
was later found to respond to iron deficiency and to respond earlier than the lowering of 
Hb concentration.  Thus EP can be used as a screening test for iron deficiency in both 
children and adults, including pregnant women (34, 55).  Schifman et al and others have 
found that the diagnostic sensitivity and predictive value of EP for evaluating iron 
depletion and risk of anemia in children and in pregnant women compared favorably with 
ferritin and transferrin saturation measurements (56-57).  The widely used technique to 
measure EP is to measure its natural fluorescence in a drop of capillary blood with a 
hematofluorometer.  Several EP cutoffs have been proposed to define iron deficiency, the 
most commonly used in the literature is >70 µmol/mol heme, but a value of >125 has 
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been suggested in areas with high prevalence of severe forms of anemia and high 
incidence of infections (58).  EP is highly correlated with iron deficiency; however, it can 
also be elevated in cases of chronic infection and lead poisoning.  Thus, EP should not be 
used as a single indicator of iron deficiency. 
Transferrin saturation (TS) is an indicator of the adequacy of iron transport to 
tissues.  It is determined by dividing serum iron concentration by transferrin 
concentration, which is measured by total iron-binding capacity.  When TS is <16%, it is 
often associated with iron deficiency.  As with other indicators of iron status, TS is 
affected by infections/inflammations, which cause it to decrease (34). 
Transferrin receptors (Tfr) are found on the surface of erythrocyte precursor cells.  
When the supply of iron is inadequate for the production of Hb, Tfrs increase, which 
make them good indicators of tissue iron depletion.  However, any other condition that 
results in a high rate of RBC turnover or increased erythropoiesis, such as hemolytic 
anemia, can also lead to an elevation of Tfrs because the iron supply cannot keep up with 
the increased demand for heme synthesis.  A widely used cutoff value for Tfr is >8.0 
µg/L (34).  Several studies have shown that Tfr is more stable than most indices of iron 
status in the face of infection/inflammation, which makes it an interesting index to use in 
West Africa.  Beesly et al (59) found that changes in Tfr levels between the infected and 
non-infected state in the same individual with malaria were <10% whereas the change in 
ferritin was fivefold.   
Because serum ferritin (SF) reflects the storage iron compartment and Tfr reflects 
the functional iron compartment, these two values have been combined into a ratio, 
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which is reciprocally regulated, the Transferrin receptor-ferritin index.  Punnonen et al 
(60) found that the log of the ratio provides an outstanding index of iron depletion when 
compared to SF and Tfr indices alone.    
There are several other red blood cell measurements that are useful in 
differentiating iron deficiency anemia from anemia due to other causes and that are easily 
measured by modern electronic blood counters.  Erythrocyte indices are useful in 
defining anemia that results from iron deficiency and mild anemia resulting from 
thalassemic trait: Mean Corpuscular Volume (MCV) and Erythrocyte distribution width 
decrease as iron deficiency becomes more severe (34). 
Hb concentration is the most widely used index of the last and most severe stage 
of iron deficiency, anemia.  Hb is traditionally measured by spectrophotometry through a 
method that was first described by Drabkins back in 1942.  Today, there are newer and 
less cumbersome methods such as the HemoCue system, which consists of a portable 
photometer and microcuvettes that contain sodium deoxycholate, sodium nitrite, sodium 
azide, and sodium fluorsceine.  When a drop of capillary blood obtained by skin puncture 
is placed on the chemically treated microcuvette, sodium deoxycholate lyses the RBCs, 
which triggers the release of Hb.  Sodium nitrite and sodium azide then convert Hb to 
methemoglobin and azide methemoglobin whose absorbance is then read by the 
photometer at a wavelength of 565 nm.  The advantages of the HemoCue system include 
the following: 1) it is useful for surveys where high accuracy is important; 2) it provides 
accurate and objective measurements comparable to Drabkins’ method; 3) the instrument 
is portable and blood specimens need no processing; 4) results are available in 45 to 60 
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seconds (61-62).  The Centers for Disease Control and Prevention (CDC) has proposed 
anemia cutoff values for pregnant women that take into account the maternal plasma 
volume expansion and therefore hemodilution: <110 g/L for the first and third trimesters 
of gestation and <105 g/L for the second trimester (63).  WHO considers that Hb levels 
below 90 g/L represent moderate to severe anemia while Hb values below 70 g/L are an 
indication of severe anemia (64).  
 
Iron deficiency: the demands of pregnancy 
Pregnant women are highly prone to iron deficiency and iron deficiency anemia 
because of their high need for the nutrient, needs that can rarely be met through diet 
alone.  The total iron costs of pregnancy can be classified into five categories and are 
estimated at as much as 1190 mg (Table 1): 1) basal iron losses from the body, 2) fetal 
iron deposition (the rate of deposition varies with the stage of pregnancy so that most of 
the deposition occurs during the second and third trimesters of gestation), 3) iron 
deposition in the placenta, 4) the iron cost of maternal plasma volume expansion, which 
occurs during the second and third trimesters and is calculated as iron needed to achieve 
an average hemoglobin concentration of 130 g/L at the end of pregnancy, and 5) maternal 
blood loss at delivery (65).   




Basal obligatory iron losses 230 
Fetal iron deposition 270 
Placental deposition 90 
Red blood cell mass expansion 450 
Maternal blood loss at delivery 150 
TOTAL COST 1190 
*Adapted from reference 65 
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If only 5% to 10% of dietary iron is available for absorption, which is often the 
case for diets in many developing countries that are low in iron absorption enhancers and 
high in iron absorption inhibitors, then dietary iron intakes of 40-80 mg/d are needed to 
meet the iron needs of pregnancy.  As mentioned above, the iron is not utilized at the 
same rate throughout pregnancy.  Dietary iron needs in the third trimester could be 60-
125mg/d in developing countries (65-66). The few dietary surveys conducted in sub-
Saharan African countries such as Senegal confirm the low availability of bioavailable 
dietary iron.  In a nutrition survey in the Lindi District of Tanzania, Tatala et al (32) 
found that the mainly cereal-based diet of their subjects (660 households; 2320 
individuals of all ages) with additional legumes and green vegetables contained high 
amounts of total iron of low bioavailability.  Estimation of the amount of iron absorbed 
and of the major cause of anemia in that region confirmed inadequate iron nutrition.  Low 
intake of iron has also been documented in the Gambia, Somalia, Kenya, Tanzania, and 
Zambia (67).  Sikosana et al (68) conducted an anemia prevalence survey among 
pregnant women in Zimbabwe from which they concluded that the 33% prevalence rate 
of iron deficiency anemia was linked to the diet of the sample subjects: the main staple 
food was maize meal porridge; beans and meats were only consumed on a weekly basis; 
however, bread and tea were consumed on a daily basis, both of which contain iron 
absorption inhibitors (i.e. phytates and tannins, respectively).    
 
1.2 Folate deficiency 
Deficiencies in hematopoeitic nutrients other than iron can also lead to anemia.  
Folate deficiency is the second most common cause of anemia after iron deficiency.  It 
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causes a megaloblastic type of anemia because folate and its derivatives are necessary for 
the synthesis of deoxyribonucleic acid (DNA) and amino acids by being coenzymes in 
one-carbon transfer reactions.  Thus a folate deficiency impairs cell division and protein 
synthesis, resulting in large, hypochromic, and immature RBCs (69).   
Folate, also known as pteroylglutamate or pteroylmonoglutamate, is made of 3 
distinct parts, which must all be present for vitamin activity: Pteridine, Para-amino 
benzoic acid (PABA), and multiple glutamic acid residues.  Pteridine is conjugated to 
PABA to form Pteroic acid; the carboxy group of PABA is then peptide bound to the 
alpha amino group of glutamic acid to form folate.  Although humans can synthesize all 
the component parts of folate, they lack the enzyme necessary for the coupling of the 
Pteridine molecule to PABA (70). Thus, folate is an essential nutrient that must be 
provided in the diet.  Folate in foods exists mostly in the form of pteroylpolyglutamates 
(which contain up to nine glutamic acid residues), the most common in foods being 
tetrahydrofolate or THF.  Good dietary sources of folate include green leafy vegetables, 
legumes, yeast, whole grains, and liver.   
Once folate is ingested, the excess glutamic acid residues of the vitamin must be 
hydrolyzed from its side chain by enzyme conjugases in the intestinal lumen because the 
bioavailability of folate monoglutamate is far greater than that of folate polyglutamate in 
humans.  Folate is then absorbed primarily from the proximal third of the small intestine.  
However, conjugase action may be specifically inhibited by food factors described in 
yeast and beans and may be non-specifically impaired at acid pH.  The absorbed folate is 
then largely converted in the intestinal lumen and enterocytes to reduced forms and then 
methylated or formylated and transferred to the circulation (69-70).  The transfer process 
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is poorly understood, but a carrier-mediated system has been suggested and identified.  
Normal total-body folate stores range from 5 to 10 mg of which about half is in the liver.  
Folate is excreted in urine and bile (about 100 µg of the biologically active vitamin is 
excreted in bile daily) (70).  
Pregnancy is characterized by a marked acceleration in one-carbon transfer 
reactions, including those required for cell division (rapidly growing fetus and placenta, 
expansion of maternal red cell mass and reproductive organs), which is why the folate 
needs of pregnant women are dramatically higher than those of non-pregnant or lactating 
women (71).  Folate bioavailability from foods varies widely from as high as 96% in 
cooked lima beans to as low as 25% in romaine lettuce.  Therefore, the dietary reference 
intake (DRI) for the vitamin is expressed in terms of “dietary folate equivalents” or DFE.  
One DFE is equivalent to 1 µg food folate or to 0.06 µg folic acid consumed in fortified 
foods or as a supplement. It is recommended that pregnant women consume 600 µg of
food folate per day in addition to 400 µg of folic acid in fortified foods or supplements, 
and 200 µg of folate from fruits and vegetables.  The Food and Agriculture Organization 
(FAO) and WHO recommend a daily folic acid supplement of 400 µg from the beginning 
to the end of pregnancy (71).   
Folate status is usually assessed by measuring serum/plasma or red blood cell 
folate.  However, serum/plasma folate levels only reflect recent dietary intake.  In 
contrast, RBC folate levels are more reflective of status because they represent vitamin 
status at the time the RBC was synthesized (70).   
The sequence of events in developing a folate deficiency is somewhat similar to 
that of developing an iron deficiency.  Early negative folate balance is characterized by a 
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drop in serum folate to below 3 ng/mL; however, neither folate stores nor RBC folate are 
affected.  The second stage of deficiency is characterized by an even lower serum folate 
and a fall in RBC below 160 ng/mL.  The third stage can be termed folate-deficient 
erythropoiesis, which is characterized by defective DNA synthesis.  The fourth and final 
stage of deficiency is manifested by gross macroovalocytosis, elevated mean corpuscular 
volume, and anemia (72).  The clinical symptoms that accompany a megaloblastic 
anemia include weakness and tiredness, sore tongue, constipation, headaches, and 
palpitations.  The most severe consequence of folate deficiency during pregnancy is 
neural tube defect in the offspring.  Studies have documented the contribution of folate 
deficiency to the prevalence of anemia in sub-Saharan Africa.  In South Malawi, Van den 
Broek et al (10) found that 52% of pregnant women in their sample were iron deficient 
(making iron deficiency the main cause of anemia) while 34% were folate deficient, 
making folate deficiency the second most frequent cause of anemia in the sample.  
Ingram et al (73) reported that the second most common cause of megaloblastic anemia 
(32%) in a sample of pregnant South African women was folate deficiency.  In the 
Congo, folate deficiency accounted for only a 5% prevalence of anemia; however, it was 
the second most prevalent nutrient deficiency in the etiology of anemia in a sample of 
pregnant women (74).  Fleming (75) described the causes of severe anemia in a small 
sample of Zambian pregnant women and found that 62% of women were folate deficient, 
a deficiency that was mostly secondary to malarial hemolysis.     
 
1.3 Malaria 
The population in sub-Saharan Africa that was exposed to stable malaria in 1995 
has been estimated at 447 million (76).  An estimated 21% of severe anemia cases among 
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pregnant women is attributable to malaria according to Guyatt and Snow’s review of 26 
research studies on the levels of Hb in all parities and in a wide range of intensities of 
malaria transmission in 26 sub-Saharan African countries, including Mali, the Gambia, 
and Mauritania (all bordering Senegal) (19).  Malaria is the leading cause of morbidity in 
Senegal. 
Malaria is caused by the Plasmodium species, especially P. falciparum. WHO 
defines severe malarial anemia as Hb concentration < 50 g/L or a hematocrit of < 15% in 
the presence of a normocytic blood film and P. falciparum parasitemia > 10,000 
parasites/µL of whole blood.  In practice, severe malarial anemia is defined at the levels 
of Hb and hematocrit cited above, but in the presence of any P. falciparum parasitemia 
(77).  The pathogenesis of malarial anemia is complex and results from both increased 
hemolysis and decreased erythropoiesis.  Increased hemolysis is due to various factors 
including phagocytosis and splenic removal of both parasitized and unparasitized 
erythrocytes, autoimmune hemolysis of unparasitized erythrocytes, and hapten-induced 
intravascular hemolysis all resulting in decreased Hb concentration below normal levels 
and therefore anemia (77).  Pregnant women in malaria endemic areas of Africa often do 
not receive adequate prenatal care to prevent and/or cure malaria.  In areas of high or 
moderate (stable) malaria transmission such as Senegal, adult women become semi-
immune to the disease so that many malarial infections are asymptomatic.  However, 
these forms of infection can contribute to mild to severe maternal anemia depending on 
the level of acquired immunity to malaria prior to pregnancy and the efficacy of immune 
responses during pregnancy (Figure 2) (78); and this anemia attributable to malaria leads 
to negative perinatal outcomes (Table 2). 
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Of the other parasites that cause malaria in humans, P. vivax is not present in 
Senegal, P. malariae and P. ovale are low and their effects are less clear.  P. falciparum 
was found to be the only parasite responsible for malaria in Dakar (Senegal) in a large 
survey involving 2,583 individuals (80).  P. falciparum infections observed in all age 
groups (1 to 80 years) was greatest (39%) between October and December, the period 
that immediately follows the rainy season.  The annual incidence of parasitemia in the 
sample was 5%.  In the 1970’s, WHO recommended that pregnant women in malaria-
endemic areas systematically receive treatment upon their first visit to a prenatal center 
followed by weekly chemoprophylaxis (78).  The most commonly used prophylactic 
drugs in prenatal clinics in Dakar are chloroquine and sulfadoxine pyrimethamine, which 
are prescribed to pregnant women in addition to the iron/folic acid tablets.  However, the 
implementation of the WHO recommendation has been hampered by several factors in 
Africa.  These factors include the spread of chloroquine resistance and poor compliance 
with a daily or weekly regimen of the drug throughout pregnancy (81).   
 
21
Figure 2: Malaria during pregnancy* 
 
*Adapted from reference 78 
 
Table 2: Malaria’s contribution to adverse health outcomes in Sub-Saharan Africa* 
 
Adverse health outcome Percentage of the total caused by 
malarial infection 
Maternal anemia 2-15 
Low birth weight 8-14 
Preterm - low birth weight 8-36 
IUGR** – low birth weight 13-70 
Infant death 3-8 
*Adapted from reference 78; **Intrauterine growth retardation 
 
1.4 Helminth infection 
WHO estimates that about 1.2 billion and 1 billion individuals around the world 
are currently infected with the hookworms (Necator Americanus and Ancylostoma 
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duodenale) and Trichuris trichuria, respectively.  Schistosomiasis and Ascaris 
lumbricoides infections are also prevalent.  Most of these individuals reside in tropical 
developing countries.  These parasites are common soil-transmitted helminths that 
propagate in areas of poverty, poor nutrition, poor sanitation, and where there are 
shortages of clean drinking water (21).   
Hookworm infection is a major contributor to iron deficiency anemia in women of 
childbearing age, including pregnant women in most developing countries and is 
associated with high maternal mortality and morbidity (21).  The hookworms are 
nematodes; transmission and infection by N. americanus depend on the penetration of 
human skin by third-stage larvae, which develop from eggs passed in human stools and 
into the environment (A. duodenale larvae can occasionally pass the placenta in the case 
of pregnant women and invade the developing fetus).  After transmission, the larvae 
migrate through tissues and then return, via the respiratory system, to the digestive tract.  
The maturing larvae will then usually invade the jejunal mucosa where eventually they 
develop into adult worms and bite into the tissues and feed on blood.  While in the small 
intestine, the female hookworms can produce thousands of eggs each day.  It is estimated 
that a single N. americanus can be responsible for a blood loss of 0.05 ml per day; a 
single A. duodenale, which is the more virulent species that can be swallowed, can be 
responsible for 0.25 ml of blood lost per day; (82).  Because of this fact, anemia from 
chronic infection follows 3 to 5 months after exposure.  Heavily infected individuals 
(>2000 eggs per gram of feces) are most at risk of developing iron deficiency anemia 
(21).  The effects of the parasites will also be mediated by the host’s iron and general 
nutritional status, by the quantity and quality of iron sources in the diet, by the ability of 
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the gut to absorb iron, and by whether the host has infections that may adversely affect 
iron status.  Pregnant women in sub-Saharan Africa are therefore especially susceptible to 
iron deficiency anemia caused by hookworms.  In a sample of 2104 near-term pregnant 
Nigerian women, Egwunyenga et al (83) found that 48% were infected with intestinal 
nematodes of which 14% were specifically infected with hookworm; Hb concentrations 
among these women were lowest (86 g/L) among those with malaria coexisting with 
helminth infection.  In Kenya, 75% of anemic pregnant women had hookworm infection 
compared to only 25% of non-anemic women (N = 279) (84).   
WHO recommends that a single dose antihelminth treatment be provided to 
pregnant women after the first trimester of gestation in areas of endemic infection (21).  
Many studies have shown the effectiveness of treatment to decrease morbidity.  In Sri 
Lanka, 115 pregnant women had marked improvements in Hb concentration when they 
were given an antihelminth drug in addition to iron/folic acid supplements (85).  A 
longitudinal study in Sierra Leone involved 184 pregnant women who were given a 
single dose of 400 mg albendazole and iron/folic acid supplements.  The women showed 
a significantly smaller decline in Hb and SF concentrations than those women who only 
received iron/folic acid (86) 
Schistosomiasis caused by S. haematobium, S. japonicum, and S. mansoni affects 
more than 200 million people worldwide, 85% of whom live on the African continent.  
The infection is acquired from water containing worm larvae, which develop in snails.  In 
1989, 71.5% of more than 2,000 routine stool examinations in St Louis (Senegal River 
Valley) tested positive for S. mansoni. In sub-Saharan Africa where there have been few 
control programs and where the population has increased by close to 70% over the past 
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25 years, many individuals are infected or at risk of infection (87).  Unfortunately, 
accurate data on country-specific prevalence of schistosomiasis are limited and therefore 
global estimates of the number of people infected must be based on extrapolations from 
the limited data generated from prevalence survey data in some countries.  Senegal is 
considered to be an area of high endemicity.  Two of the schistosome species are 
responsible for increased blood loss that can lead to iron deficiency anemia.  S.
haematobium causes chronic bleeding into the urinary tract while S. mansoni causes 
bleeding into the large intestine but both infections can contribute to the anemia of 
pregnancy (82). 
Trichuris trichiura or the whipworm is transmitted feco-orally; once the infective 
egg is swallowed, it hatches; larvae invade the mucosa of the small intestine and mature 
in the large intestine.  The mature worms then remain in the large intestine and feed on 
tissues therefore causing blood loss.  Each worm can cause blood loss of about 0.005 ml 
per day; thus, a heavy T. trichiura infection can cause iron deficiency that can lead to 
anemia.  A single female worm can produce up to 70 eggs per day (21-22). 
Ascaris lumbricoides or the roundworm is transmitted in a similar fashion as the 
whipworm.  A female nematode can produce >200,000 eggs per day in the small 
intestine.  Adult worms then latch on to the intestinal tissues and cause blood loss.  A. 
lumbricoides infection is believed to affect more than 10 million individuals in Africa 
alone (22). 
Hookworm, T. trichiuria, A. lumbricoides, and S. mansoni infections are believed 
to be prevalent in Dakar, Senegal (93).  
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1.5 Hemoglobin variants 
The normal Hb molecule is a tetramer of two pairs of unlike globin chains with 
each chain sharing a covalent bond with a heme group.  Normal types of Hb have α
chains combined with β(Hb A, α2β2), δ chains (Hb A2, α2 δ2), or γ chains (Hb F, α2γ2).  
As with all polypeptides that perform specific functions in the human body, Hb has a 
specific sequence of amino acids.  Inherited Hb variants or disorders can either result 
from structural mutations in the sequencing of the amino acids or mutations in the 
molecular structure of Hb (thalassemias).  The structural Hb variants mostly result from 
single amino acid substitutions in the α or β chains.  Over 700 structural Hb variants have 
been identified; however, only three of them, Hb S, Hb C, and Hb E, are prevalent around 
the world (15).  In many cases, these substitutions are innocuous, but in others, 
substitutions may affect the stability and function of Hb, thus leading to a clinical 
disorder.  
Such is the case with sickle cell Hb, or homozygous Hb SS, which was first identified in 
1945 when Pauling discovered that the normal Hb A has an anionic charge two units 
more negative than that of Hb S.  About ten years after Pauling’s discovery, Ingram 
demonstrated that the charge difference between the two forms of Hb results from the 
replacement of the Glu residue in the 6th position of each of the Hb A β chains with a Val 
residue in the Hb S β chains (88).  Hb variants are hereditary.  For example, if two 
individuals both have Hb AS (heterozygous sicklers) and have children, half of their 
offspring will also have Hb AS, while one fourth will have normal Hb AA, and the 
remaining one fourth will be homozygous sicklers (Hb SS).  For the latter, the amino acid 
mutation in Hb causes Hb S to aggregate into filaments when deoxygenated.  These 
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filaments are of sufficient size and stiffness to give red blood cells an irregular crescent-
like shape (or sickled shape) that causes vaso-occlusion.  Individuals with Hb SC and Hb 
S [Hyphen] β-thalassemia are also homozygous sicklers.  During a sickle cell crisis, the 
blood flow through tissues is decreased and may be completely blocked in some areas 
thereby creating severe pain and tissue damage.  These crises include episodes of 
sequestration of blood into the lungs, liver, or spleen, infection, or the occlusion of 
cerebral vessels with resulting stroke.  Furthermore, because of their mechanical fragility, 
the life span of erythrocytes is reduced to 60 days instead of the normal 120 days, leading 
to hemolytic anemia in individuals with homozygous Hb SS, thus the term sickle cell 
anemia (88).  In sub-Saharan Africa, Hb S gene frequency reaches 0.15 in some 
populations in which about 30% of adults have sickle cell trait and 2% of newborns have 
homozygous sickle cell anemia.  In Senegal, the Hb S gene frequency is greater than 0.02 
(89-90).  The heterozygous state for sickle cell, Hb AS and Hb SC, often results in a 
milder form of sickle cell anemia.  It is associated with a high frequency of aseptic 
necrosis of the femoral or humoral heads, hematuria, proliferative retinopathy, and a 
thrombotic tendency, which in pregnancy may lead to massive pulmonary thrombo-
embolic disease and death (89).  Hemoglobin C is another mutation in the gene for the β
chain. About 2-3% of people of West African descent are heterozygotes for hemoglobin 
C.  Hemoglobin C disease (seen in homozygotes) is rare and relatively mild.   It usually 
causes mild hemolytic anemia and a mild to moderate enlargement of the spleen. 
 Thalassemias are another form of Hb variants in which globin chain production is 
reduced.  Thalassemias are classified as the α or β types depending on whether the α or β
chains are reduced.  The symptoms of α thalassemia are variable.  The milder forms in 
27
their homozygous state produce a mild hypochromic anemia.  The more virulent forms 
can result in stillbirth and extremely difficult pregnancies.  The carrier frequency of the 
milder forms of α and β thalassemia is as high as 10% to 20% in sub-Saharan Africa 
(88). 
 
1.6 Chronic infection 
In otherwise healthy populations, anemia is generally caused by nutritional 
deficiencies.  However, in many developing countries anemia due to chronic infectious 
and/or inflammatory diseases, also known as the anemia of chronic disease (ACD) is also 
common.    
The pathogenesis of ACD is thought to involve immune activation from contact 
with either a foreign infectious agent or a foreign neoplasm.  This activation releases 
cytokines (i.e. tumor necrosis factor, interleukin-1, gamma-interferon, and beta-
interferon), which lead to the inhibition of colony-forming units-erythroid (CFU-E) 
development (i.e. reduced erythropoiesis) and produce anemia (91).  ACD is one of the 
most frequent forms of anemia encountered in sub-Saharan Africa and among pregnant 
women, especially with the growing numbers of HIV/AIDS infections.  In a sample on 
1064 HIV –infected pregnant Tanzanian women, iron deficiency and infectious diseases 
were found to be the predominant causes of anemia (92).  Fortunately, Senegal has one of 
the lowest prevalence of the disease in sub-Saharan Africa with an estimated 1.7%.  
Nevertheless, other forms of chronic infection are prevalent during pregnancy, such as 
tetanus, yellow fever, respiratory infections, and tuberculosis (93).     
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2. Consequences of anemia during pregnancy: why it is important to treat the disease
Several studies have supported the correlation between anemia or iron deficiency 
anemia and increased risk of preterm delivery and low birth weight.  Since birth weight is 
the strongest predictor of perinatal mortality, the eradication of anemia during pregnancy, 
especially in developing countries where health care is often limited, is a necessity.   
Strong evidence indicates that there is an association between maternal 
hemoglobin concentration and birth weight and preterm birth (23, 94-96).  Anemia, 
especially during the second and third trimesters of gestation, has also been linked to 
increased risk of small-for-gestational age (97).  Scholl et al (98) found a strong 
association between anemia specifically caused by iron deficiency and preterm delivery.  
Furthermore, a recent study by Cogswell et al (24) has added promising new evidence 
that iron supplementation during pregnancy improves birth weight.   
Although WHO has issued statistics on maternal mortality attributable to anemia, 
the relationship remains a source of controversy.  Researchers do agree though that there 
is a proportion of maternal mortality in developing countries that is attributable to 
anemia, especially severe anemia (99).  They also agree that iron deficiency is likely to 
be a major contributory cause.   
 
3. Interventions to combat iron deficiency and iron deficiency anemia
Various intervention strategies have been employed to control iron deficiency anemia 
among pregnant women around the world.  They include dietary diversification, iron 
fortification of widely accessible staple foods, iron supplementation, and parasite control.  
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The nature of the intervention that best controls the disease depends on the context (i.e. 
available physical, human, and financial resources and the target population).  
 
3.1 Food-based interventions 
If a fortifiable food consumed by many in the target population exists, in this case 
iron deficient/anemic pregnant women, fortification can be a cost-effective strategy to 
control the disease (100).  There is no national policy for iron fortification programs in 
Senegal even though there are many staples, such as rice and millet, which are fortifiable.  
In West Africa, only Nigeria is exploring the possibility of dual fortification of salt with 
iodine and iron.  Mali, Burkina Faso, and Cote d’Ivoire are exploring the possibilities of 
fortifying sugar, bouillon cubes, and wheat flour.  Fortification of wheat flour is 
technically relatively easily done; it has worked in countries in South America and the 
Caribbean (101).  The possibility of fortifying processed foods sold in the streets of 
Dakar has been suggested since large numbers of the population consume those foods 
(102). 
General nutrition education messages have proven effective for controlling iron 
deficiency anemia, even when poverty limits dietary choices.  Pregnant women should be 
educated to consume foods that are high in iron, even if bioavailability is low (103).  
Even though there are some nutrition education programs for pregnant women led mostly 
by non-governmental and charitable organizations in Senegal, there is no national 
program to specifically inform women on proper iron nutrition.    
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3.2 Helminth control 
As previously mentioned, in areas where intestinal parasite infection is endemic and 
anemia is very prevalent, parasitic infection is likely to be an important cause of 
moderate to severe anemia.  WHO recommends that in these areas, anthelminthic 
treatment (in combination with iron/folic acid supplements) be given prophylactically to 
pregnant women suffering from severe anemia.  The treatment is safe and much less 
expensive than diagnosing parasitic infection.  The combination of chemotherapy and 
iron/folic acid supplements enhances the Hb response to supplementation; mebendazole, 
albendazole, levamisole, and pyrantel may all be safely administered to pregnant women 
after the first trimester (21,103).  There is no national policy for the control of 
helminthiasis among pregnant women in Senegal.  
 
3.3 Malaria control 
Where P. falciparum or other Plasmodium species are endemic, detecting and treating 
malaria is an essential part of the control of anemia among pregnant women.  Several 
studies in Burkina Faso and other African countries have shown that the proper usage of 
insecticide-treated bed nets (ITNs) can decrease the prevalence of severe anemia in 
young children and decrease infant mortality by up to one third (100).  The same could be 
true for pregnant women; however, the evidence is less clear.  In Senegal, 33% of 
pregnant women use bed nets; however, only 10% of those use treated bed nets (106).  
Malaria prophylaxis combined with iron/folic acid supplements has proven more 
effective than supplements alone (78-81).  The Senegalese national policy for malaria 
control among pregnant women consists of prescribing chloroquine or sulfadoxine 
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pyrimethamine prophylactically to all pregnant women who attend public prenatal 
clinics.  
 
3.4 Reproductive intervention 
Attempts to decrease the prevalence of iron deficiency anemia among pregnant 
women also include preventing early or adolescent pregnancies, which can lead to 
complications not just because of the gynecological immaturity of adolescents but also 
because of the competition for nutrients between the growing adolescent and her growing 
fetus (105).  According to the 2005 Demographic and Health Survey (DHS) for Senegal, 
19% and 38% of 17 and 19-year old adolescents, respectively, already have children.   
Because of the efforts of the Senegalese Ministry of Health and of non-governmental 
organizations to initiate education programs and promote birth control to reduce 
adolescent pregnancy, the median age at which women have their first child in Dakar is 
22 years.  Only 9% of girls aged 15-19 years experience pregnancies compared to 30% in 
rural areas (106). 
In addition to reducing the number of adolescent pregnancies, reducing gravidity 
in women and increasing the interval between pregnancies will also contribute to the 
control of iron deficiency anemia in women.  When this interval is two or more years, 
women are more likely to enter the subsequent pregnancy with adequate iron status if 
dietary iron deficiency is not severe (103). 
3.5 Iron supplementation 
Of the strategies that have commonly been used to combat iron deficiency and 
iron deficiency anemia among pregnant women, supplementation is by far the most 
32
widespread in sub-Saharan Africa.  The decision to supplement any population group 
should be and is usually based on the likelihood of iron deficiency in the target 
population and on the potential benefits of supplementation.  Thus, pregnant women are 
excellent candidates for supplementation because they are more prone to iron deficiency 
than other groups and because clinical trials have shown that women who are 
supplemented with iron during pregnancy have improved iron and Hb status compared to 
women who are not supplemented. 
 
3.6 Selecting the appropriate intervention 
According to a International Nutritional Anemia Consultative Group (INACG) 
report (103), the appropriateness of an intervention for a specific region depends on three 
factors.  First, it is important to define the epidemiology of anemia in that region; in other 
words, one needs to determine what populations are most at risk of anemia and very 
importantly the etiology of anemia.  No published epidemiological information of this 
sort is yet available for Senegal; in this case, it is safe to assume that young children and 
pregnant women are at greatest risk for anemia because of their high physiological 
demands for iron.  The second factor that determines an appropriate intervention is the 
available infrastructures that determine the cost and feasibility of the different 
approaches.  As is the case in most developing countries, prenatal care clinics in Senegal 
are the strategic and chosen structures of intervention in the case of pregnant women.  
However, by definition, the same intervention does not reach those women who do not 
seek prenatal care or who do not seek it early enough during pregnancy for effective 
intervention.  The third factor that determines the appropriateness and success of an 
intervention is the acceptability of the intervention by the health care workers and by the 
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community being served.  It is important that this community develops a sense of active 
partnership with the health system based on their conviction that the intervention is 
designed to benefit the members of the community.  This third factor is often absent from 
prenatal care programs in developing countries, including Senegal.  Figure 3 summarizes 
the elements of successful iron supplementation programs. 
The monitoring and evaluation of iron supplementation programs are essential to 
their success.  Monitoring is the process of continually collecting information about the 
different parts of the program while evaluation may be periodic and involves judgment 
about whether the program is effective (103).  In the case of iron supplementation 
programs for pregnant women, the effectiveness of the program can be judged by 
whether it fosters a significant improvement in women’s iron status and therefore 
decrease the incidence and prevalence of anemia during pregnancy.  Further judgment 
can be based on whether supplementation improves pregnancy outcome, whether women 




Figure 3: Elements of successful iron supplementation programs (Adapted from 
reference 103) 
 
4. The iron supplementation program for pregnant women in Senegal
The iron supplementation program for pregnant women in Senegal was 
implemented in the 1990’s in all public health centers that deliver prenatal care in the 




• Adequate budget 
• Data-based ordering 
number in target 
group + 35% 
surplus 
• Timely ordering 




• Accessible to target 
group 






• Good quality 
supplements 





Do intended recipients get 
supplements? 
COMPLIANCE 
Do recipients take the supplements? 
IMPACT 
Reduction of iron deficiency anemia 
Policy-making 
Monitoring and Evaluation 
35
purchase iron/folic acid tablets after a physical examination.  The supplement tablets 
contain 65 mg of elemental iron (as 200 mg of ferrous sulphate) and 250 µg of folic acid.  
Women are directed to purchase as many tablets as necessary for daily supplementation 
until the end of pregnancy.  The iron/folic acid tablets are supposed to be available for 
purchase at the health center pharmacies.   
 The Senegalese program is only partly monitored and not evaluated.  The 
monitoring that is conducted by the Ministry of Health is actually a monitoring of 
prenatal care services as a whole: every six months, the Ministry of Health delegates a 
team to the health centers in Dakar and elsewhere to determine: 1) the number of women 
who have attended the center to receive prenatal care; 2) whether they all received the 
needed clinical examinations; 3) whether blood and urine samples were given for 
analyses; and 4) whether they all received a prescription for iron/folic acid tablets and 
malaria chemoprophylaxis.  However, data is not collected on whether the women have 
actually purchased and taken the supplements.  Thus, there is no data currently available 
on whether the Senegalese iron supplementation program fosters adequate compliance to 
reduce the prevalence of iron deficiency anemia among pregnant women.  The absence of 
an evaluation of this program means that the potential problems of this program may 
never be identified so that the program can be improved. 
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5. Iron supplementation of pregnant women clinically improves their iron status: have 
supplementation programs around the world contributed to decreasing the prevalence 
of anemia? Why or why not?
5.1 A selective review of iron supplementation trials 
Since the late 1960’s, a large number of iron supplementation trials have 
demonstrated the efficacy of iron supplementation in improving the health of pregnant 
women.  Sloan et al (107) have presented a comprehensive review of the impact of iron 
supplementation on maternal Hb in 23 randomized controlled trials, 15 of which were 
conducted in developing countries (including The Gambia, Nigeria, Tanzania, and South 
Africa) and all were published in peer-reviewed journals between 1966 and 1998.  
Almost all studies drew their samples from women attending prenatal clinics; 2 drew 
their samples from rural prenatal centers.  The authors found that iron supplementation 
alone increased Hb concentration by 10±0.13 g/L (P<0.001, n = 1118).  Women 
receiving iron combined with folic acid had 13.7±0.93 g/L (P<0.001) better change in Hb 
concentration than did women not receiving supplements.  In studies reporting a change 
in SF, iron supplementation alone improved SF concentration by 9.48±0.0174 µg/L 
(P<0.001, n = 578).  Iron supplementation alone reduced the proportion of women with 
Hb concentrations <110 g/L (considered anemic by WHO standards) by 38%.  The effect 
of iron supplementation was greatest in women from developing countries with the 
lowest baseline Hb concentrations.  The dose of iron administered to women varied from 
one study to the next.  The authors found a positive dose response relationship between 
iron dose and change: those women receiving no more than 60 mg of daily iron had the 
lowest change in Hb concentration compared to women who were receiving 61-90 mg, 
91-120 mg, and >120 mg iron daily (Table 3). 
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Table 3: Meta-analysis of trials of iron supplementation during pregnancy1
Daily dose of elemental iron and mean 
initial Hb concentration and effect 
Mean change compared with control 
subjects (g/L) 
Daily dose (mg Fe/d)2
≤60 2 (-17-11) 
61-90 10 (6-15) 
91-120 12 (6-22) 
>120 16 (9-26) 
Mean initial Hb (g/L)3
≤100 10 (2-17) 
 <110 13 (-3 to 25) 
 <120 5 (-12 to 12) 
 ≥120 __ (---) 
1Adapted from reference 107 
2Data from all countries 
3Data from developing countries only 
WHO makes the following recommendations for supplement dosage: where the 
prevalence of anemia is <40%, pregnant women should routinely receive a daily 
supplement containing 60 mg of elemental iron and 400 µg of folic acid for 6 months 
during pregnancy; where prevalence of anemia is ≥40%, the same treatment should be 
given for 6 months during pregnancy and continued until 3 months postpartum.  WHO 
further advises that in either case, if the full 6 months of supplementation cannot be 
achieved, that the daily dosage should be increased to 120 mg of iron or that postpartum 
supplementation should continue for 6 months.  If the recommended dosage of 400 µg of 
folic acid is not available, the widespread tablets of 250 µg should be used until higher 
doses are available (103).  
 According to the Sloan et al meta-analysis, in addition to the dose of iron, the duration of 
supplementation is also linked to the magnitude of improvement of Hb: countries 
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providing up to 10 weeks, 11 to 13 weeks, and 14 to 19 weeks of iron found benefits 
relative to no supplementation. 
The bulk of iron supplementation trials of pregnant women were done in South 
East Asia where the prevalence of anemia among pregnant women is the highest in the 
world.  Studies conducted specifically in sub-Saharan African countries, which have the 
second highest prevalence of anemia worldwide, are fewer but support the assertion that 
under certain conditions, iron supplementation, often in combination with at least one 
other nutrient, improves iron status and decreases the incidence of anemia among 
pregnant women.  The following is a brief review of such studies. 
Jackson and Latham (108) reported a 33% decline (78% at enrollment to 45% at 
term) in the prevalence of anemia among pregnant Liberian women (N = 621) 
supplemented with 60 mg of iron at different frequencies (once daily or thrice daily) 
and/or 500 µg of folic acid and/or anti-malarial drugs over 12 weeks of supplementation.  
This study showed the benefits of supplementation when there is a high prevalence of 
anemia and when supplementation is given late in the second trimester of gestation and 
early in the third when nutrient needs for both the developing human and the mother are 
greatest (88% of women in the Liberian sample were 24 weeks pregnant at enrollment).  
In a follow-up study involving a sub-sample of the Liberian women (n = 80), Jackson et 
al (109) found that there was a positive and significant correlation between maternal Hb 
concentration at 6 months of gestation and infant birth weight. 
In a randomized, double-blind, controlled clinical trial, Semba et al (14) found 
that pregnant women in Malawi (n = 109) who were supplemented with a lower dose of 
iron than in the previous study (30 mg) and 400 µg of folic acid daily from 23 weeks 
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(enrollment) to 38 weeks of gestation had a mean Hb improvement of 7.3 ± 2.3 g/L (P = 
0.003).  The prevalence of anemia of 50% at enrollment was reduced to 35% at 38 weeks.   
Another supplementation trial in rural Malawi (110) compared a weekly iron/folic 
acid supplement (120 mg iron, 500 µg folic acid) to a daily regimen (60 mg iron, 250 µg
folic acid) in pregnant women attending a prenatal clinic.  The women were stratified by 
grade of anemia at enrollment and randomly assigned to either group (n1 = 202; n2 = 
211).  Supplementation was continued for an average of 10 weeks.  The mean final Hb 
concentrations of both groups significantly increased compared to initial Hb by the end of 
the trial, but did not significantly differ from each other.  Compliance as indicated by 
self-reports and pill counts was significantly higher in the weekly group (76% compared 
with 60%, P<0.05); however, compliance was equal in both groups as assessed by a stool 
test for elemental iron.  Even though weekly supplementation did significantly decrease 
the incidence of side effects in women, it had similar hematologic effects than daily 
supplementation when administered through an existing primary health care unit. 
In Niamey (Niger), Preziosi et al (111) demonstrated the benefits of iron 
supplementation during pregnancy and during the postpartum period on both the mothers 
and their infants.  The authors conducted a placebo-controlled trial where women in their 
third trimester of gestation (n = 197; stage of gestation: 28 weeks ±21 days) were 
randomly assigned to either receive 100 mg of elemental iron throughout the remainder 
of their pregnancies or to receive placebo.  At delivery (after 3 month of 
supplementation) women in the treatment group had a significantly better iron status than 
women in the placebo group as measured by higher Hb, hematocrit, mean corpuscular 
volume, serum iron, and SF concentrations and lower EP concentration.  These 
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hematologic differences persisted 3 months postpartum: the prevalence of anemia had 
decreased in both groups but was significantly higher in the placebo group.  The 
prevalence of anemia decreased by 24% from enrollment to delivery in the iron group (66 
to 42%) while it remained constant in the placebo group.  The benefits of maternal iron 
supplementation on infants were noted in the infants’ SF concentrations at 3 months 
postpartum: they were significantly higher than for infants in the placebo group.  
Furthermore, mean length and Apgar scores were also significantly higher in the iron 
group.  These results show that iron supplementation even when started late in gestation 
have positive effects on the course and outcome of pregnancy. 
In Abidjan (Cote d’Ivoire), Carré et al (112) provided iron supplements and 
malaria prophylactics to pregnant women (n = 631) during their first prenatal visit at 4 
antenatal clinics.  Most of the women were in their second trimester of gestation (69%) at 
enrollment and were given enough supplements to carry them until term.  Hb 
concentration increased from 104 g/L at enrollment to 109 g/L at term; consequently, the 
prevalence of anemia decreased from 63 to 50% (P <0.01).  This study suggests the 
importance of making iron supplements available to pregnant women to combat anemia. 
In Western Uganda (113), the effect of daily iron (60 mg) and weekly folic acid 
(400 µg) supplementation on maternal Hb was investigated in a sample of pregnant 
women in a randomized, double-blind, placebo-controlled intervention trial.  This 
treatment was compared to the effects of chloroquine prophylaxis alone or passive case 
management alone.  The importance of combining iron/folic acid supplementation with 
malaria prophylaxis was evident; the authors found that it significantly increased 
maternal Hb concentrations during pregnancy as compared to case management (P = 
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0.01and P = 0.007, respectively) and the increase was positively correlated with the 
duration of the intervention.   
The following lessons can be drawn from this selective review of iron 
supplementation trials in sub-Saharan Africa: 1) iron/folic acid supplementation is 
effective in decreasing the prevalence of anemia and improving the iron status of 
pregnant women both in urban and rural settings in the region; 2) combining the 
supplements with malaria prophylaxis increases their efficacy; 3) this combination 
remains efficacious even when given late in pregnancy; 4) an improved maternal 
hematologic profile, improves pregnancy outcome. 
 
5.2 Success or failure of iron supplementation programs: has the prevalence of 
anemia among pregnant women decreased worldwide? 
 
Despite the demonstrated efficacy of iron supplementation in the clinical setting, 
community-wide and population-based iron supplementation programs in the developing 
world have been much less successful.  Since the 1972 WHO global policy 
recommendations to supplement all pregnant women with iron/folic acid in developing 
countries, more than half of those countries report having implemented national 
supplementation programs; however, the prevalence of the anemia of pregnancy has not 
decreased according to a United Nations report based on worldwide anemia surveillance 
data (114).    It has been suggested that until 80% of pregnant women are taking the 
recommended number of iron tablets, the worldwide prevalence of anemia will not 
decrease.  The Demographic and Health Surveys from various countries do not indicate 
this level of coverage.  In Tanzania (1999), Eritrea (1996-1997), and Yemen only 44%, 
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30%, and 21% of pregnant women receive iron supplements, respectively.  Higher rates 
were reported for Ghana (25).   
 
5.3 Factors that affect the effectiveness of supplementation programs 
Several scientists, including Sloan et al (115), Yip (116-118), and Cook and 
Reddy (119) have reflected on the discrepancy between the results of clinical trials and 
population-based iron supplementation trials.  The failure of programs is thought to be 
due to a combination of factors.   
The factor that is most often cited is low compliance of women with the 
recommended dosage and frequency of intake of supplements.  This low compliance is 
related to at least two factors, the occurrence of side effects and women’s limited 
knowledge about anemia.  Side effects that have been noted include heartburn, nausea, 
vomiting, constipation, and dark stools and are dose dependent.  A recent study in 
Bangladesh (120) suggests that a dose of iron of 30-60 mg per day may have a low or 
acceptable level of gastrointestinal side effects but did not find that the occurrence of side 
effects was a significant determinant of compliance when daily was compared to weekly 
supplementation.  Furthermore, experiences from many countries including India, 
Indonesia, and Bangladesh have shown that systematic counseling on methods to prevent 
or ameliorate side effects enhances compliance.  The counseling includes explaining to 
women that they should take iron with food, preferably in the evening, and explaining to 
them that most of the side effects are transient.  Side effects may not play as big a role in 
compliance as originally thought though.  In a study of women’s perceptions of iron 
deficiency and anemia prevention and control in eight developing countries, Galloway et 
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al (121) found that only one tenth of women stopped taking iron tablets due to side 
effects.   
Women’s knowledge about anemia and the utility of iron tablets is thought to be even 
more important factors that influence compliance than side effects.  In a qualitative study 
in urban and rural Nigeria among women attending prenatal clinics, Ejidokun (27) found 
that maternal anemia was not perceived as a priority health problem by pregnant women; 
their knowledge of the signs and symptoms of anemia was very limited.  Furthermore, 
women attributed adverse health outcomes, such as severe blood loss at delivery, to the 
use of iron/folic acid supplements.  Among pregnant Liberian women, Jackson et al (123) 
found that women’s traditional attitudes toward pregnancy minimized the symptoms of 
anemia.  Galloway et al (121) reported beliefs among pregnant women against 
consuming medications during pregnancy and fears that consuming too much iron may 
make one’s baby “big”, making delivery difficult.  Studies have shown that when women 
are better informed about anemia and its treatment, compliance increases (124).  This 
lack of knowledge about anemia and suspicion about iron tablets is also due to inadequate 
counseling from health care workers (midwives in Senegal).  In most of the countries 
studied in the Galloway et al (121) study, women attending prenatal services recognized 
iron tablets and may take them as instructed, but were not told why they are prescribed or 
how to take them.  In the Nigerian study (27), the author found that health care providers 
themselves often did not recognize maternal complications associated with anemia. 
A second major barrier to the success of programs is the limited availability and 
access to the iron tablets.  Prenatal clinics, where most supplementation programs are 
implemented, often run out of stock.  This problem does exist in Senegalese clinics 
44
whose pharmacies are supplied in tablets by the National Pharmacy, which obtains its 
stock for the most part from the United Nations. 
A third barrier to program success is the use of iron to treat anemia when iron 
deficiency is not the primary cause of anemia.  As was discussed in previous sections, 
anemia has multiple causes in sub-Saharan Africa and more studies investigating its 
etiology in specific countries are needed in order to “customize” anemia intervention 
programs. 
Table 4 presents a summary of behavior goals that foster effective iron 
supplementation programs and challenges to those goals in the real world.  Programs that 
have proven more successful than others with using iron/folic acid supplementation to 
prevent and control iron deficiency and anemia in pregnant women have focused on 1) 
increasing availability of supplements, 2) increasing acceptability of iron/folic acid 
tablets, 3) improving provider performance, 4) increasing compliance, and 5) 
encouraging iron supplementation earlier in life (124). 
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Table 4: Behavior goals and challenges of an effective iron supplementation   
program* 
Agent Behavior Goal Challenges 
Pregnant women  Obtain and use iron 
supplements at the right 
dose and frequency 
-Women not asking for services or 
knowing where they are. 
-Lack of awareness of anemia and 
how to prevent it. 
-Lack of knowledge on how to 
manage side effects. 
-Fears, beliefs, and suspicions (e.g. 
iron pills will make the baby too 




Health care providers/midwives Distribute or prescribe iron 
supplements and counsel 
women properly about their 
use 
-Lack of awareness and knowledge 
-Poor communication skills 
-Infrequent contacts with pregnant 
women  
-Providers may act disrespectfully 
towards women 
 
Health planners and drug 
managers 
Train and supervise staff, 
monitor supplies, and 
manage resources 
-Lack of awareness of purpose of 
program 
 
Agents in complementary 
services (e.g. family planning 
and pediatrics) 
-Support and reinforce 
messages of iron 
supplementation program 
-Integrate anemia education 
into their activities 
 
-Lack of awareness of anemia and 
iron supplementation activities 
-False sense of competition or threat 
between health care workers 
 
Policy makers Make and enforce necessary 
policies and allocate 
sufficient resources 
Lack of awareness of cost of iron 
deficiency anemia to health and 
economy of society 
*Adapted from reference 103 
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Chapter 3: Senegal 
 
1. History and Geography
The Republic of Senegal is located on the west coast of Africa.  It covers an area 
of 196,722 square kilometers, making it slightly smaller than South Dakota.  It is 
bordered by the Islamic Republic of Mauritania, the Republic of Mali, Guinea and 
Guinea-Bissau, the Gambia, and in the west by the Atlantic Ocean (with a coastline of 
531 kilometers) (124).  The location of Senegal in relation to neighboring countries is 
shown on Figure 4. Most of the terrain in Senegal is composed of low, rolling plains 
rising to foothills in the southeast.  In fact, the country’s highest peak, Mount Assirik, 
stands only at 581 meters near Nepen Diakha in the south.  The climate in Senegal is 
tropical.  It is composed of a rainy season, which is accompanied by southeast winds and 
extends from May to November; and of a dry season, which extends from December to 
April (accompanied by dry harmattan winds) (124). 
The region that later became Senegal was settled in the middle of the first 
millennium A.D. by Wolof and Serer peoples followed by the Tukolor (9th century A.D.) 
whose state of Tekur dominated the Senegal River Valley until the 14th century.  The 
territory of Senegal was occupied successively by the Portuguese, the Dutch, and lastly 
the French who established it as a colony in 1895.  Senegal remained part of French West 




According to the most recent census data, the population of Senegal is estimated 
at 10,284,929 million individuals who are unevenly distributed across the land.  The 
capital city, Dakar, which constitutes only 0.3% of the territory, is home to 22% of the 
total population and 80% of the urban population.  
The Senegalese population is composed of a number of ethnic groups (Table 5). 
The Wolofs constitute the largest group, representing 43% of the total population (106).  
Most people in Senegal are Muslim (94%); Christians, Animists, and individuals of other 






Figure 4. Map of Africa 
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Table 5: Ethnic composition of the Senegalese population  









*Total population is estimated at 10,284,929 
 
The Senegalese are a young people; 58% of the population is 20 years of age or 
younger and only 3% are 65 years of age and over (Table 6).  The population rate of 
growth is estimated at 3%, which is fairly high in part due to the high fecundity rate.  
Senegalese women have on average 5.3 children over the course of their reproductive 
years (106).   
 
Table 6: Age structure of the Senegalese population 
Age Group (years) Percent Total Population* 
≤ 20 58 
0- 14 45 
15-64 52 
≥ 65 3
* Total population is estimated at 10,284,929 
 
The literacy rates in Senegal are relatively low.  Only 33% of the total population 




Table 7: Selected Senegalese health statistics 
Statistic Rate 
Fecundity rate 6 children/woman (on average) 
Birth rate 38 births/1,000 
Infant mortality rate 58 deaths/1,000 live births 
Maternal mortality rate 560 deaths/100,000 births 
Rate of low birth weight 15% 
As seen on Table 7, infant and maternal mortality rates are very high in Senegal 
even when these rates are compared to rates in other West African countries of similar 
income (92).  Among the chief contributing factors to these high rates is the poor 
monitoring of pregnancies (including a high proportion of women delivering infants 
without professional assistance) resulting in poorly treated bouts of malaria, various 
causes of dystocia, and untreated nutritional deficiencies (especially iron).  Indeed, only 
12% of at-risk pregnancies are detected during prenatal visits.  These problems are 
compounded by the fatigue and malnutrition due to short intervals during pregnancy (6% 
of births occur less than 18 months before the previous one and nearly 12% of births 
occur 18 months to two years after the previous birth), precocious pregnancies (18% of 
women between the ages of 15 and 19 years have given birth at least once), and 
advanced-age pregnancies (106).  
Eighty three percent of women aged 20-34 years do seek antenatal care across 
Senegal.  The overall rate of the first prenatal visit is only 50% though and the percentage 
of women who attend the follow-up visits decreases to 32% and 20% on the second and 
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third visits, respectively.  In Dakar, antenatal care is provided in public hospitals, in 
health centers, or in private facilities for the few who can afford them.  Unfortunately, the 
frequency of antenatal visits decreases as parity increases; 87% of primipares seek care 
while only 78% of women who have had six children or more seek help (106, 126).  Only 
23% of women obtain their first prenatal visit before 4 months of gestation (106). 
 Life expectancy is only 54 years for men and 57 years for women.  However, 
Senegal is one of the few countries in Sub-Saharan Africa where the HIV/AIDS epidemic 
is under control.  Prevalence of the disease among adults is estimated to be 1.7%.  
Malaria remains the most preoccupying epidemic in Senegal.  One third of all visits to 
hospitals, clinics, and health centers are because of malaria (127). 
On average, 7% to 8% of Senegal’s annual budget is devoted to public health in 
addition to the contributions of multi-lateral and non-governmental agencies and the 
private sector (106).  
 
4. Organization of the health care system (reference 127)
The Senegalese territory is divided into ten medical regions, which have at least 
one hospital each: Dakar, Djourbel, Fatick, Kaolack, Kolda, Louga, Saint-Louis, Tamba, 
Thies, and Ziguinchor.  Each of these regions is subdivided into health districts, which 
may contain one or several health centers.  Each health center oversees several health 
posts that are dependent on the larger center and dispense basic health care services.     
The medical region of Dakar is the largest in Senegal.  It has seven hospitals; it is 
subdivided into 8 health districts, 11 health centers, and 130 health posts (Figure 5).  
Each health district serves 200,000 to 300,000 inhabitants.  Each health center is staffed 
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with a general practitioner medical doctor, a pediatric doctor, an obstetrician-
gynecologist, two dentists (not in all cases), a variable number of midwives (depending 
on the size of the center), and a pharmacist.  All centers are under the jurisdiction of the 
Ministry of Health and deliver the same package of health care services.  These include 
maternity care, both prenatal and postnatal and at a low cost.  The first prenatal visit, 
which includes a clinical examination and laboratory blood work, costs on average $2.00; 
subsequent visits cost about $1.00 each.  Prenatal care is delivered primarily by midwives 
who are trained at government accredited Midwifery Schools.  The health center doctor 
only intervenes if patients show signs of pathology in which case they are most often 
referred to the district hospital for treatment.  Typically, there are 500-600 births per 
month at each center; however, up to 1,000 pregnant women attend each clinic. This 
disparity is due to the fact that women do not necessarily give birth where they receive 
prenatal care; in addition, many women give birth at home (20%) (106). 
There is only one health center for every 180,000 inhabitants in Dakar.  This is far 
from the WHO norm of one health center for every 50,000 inhabitants.  The ratio of 
health care workers in these centers to patients has been steadily decreasing in recent 
years in part due to the rapid population growth of Dakar but also to a decrease in the 
number of health professionals.  In Dakar, there is only one physician for 3,952 
inhabitants and one midwife for 1,358 women of reproductive age (15-49 years) (127). 
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MEDICAL REGION OF DAKAR















Figure 5. Organization of the health delivery system in Dakar, Senegal
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5. The Economy
Senegal is considered a poor or developing country.  The World Bank estimates 
Senegal’s gross domestic product (GDP) at $22 billion and GDP per capita at $1,800.  
The composition of the GDP by sector is the following: agriculture = 19%, industry = 
20% (agricultural and fish processing, phosphate mining, fertilizer production, petroleum 
refining), and services = 61% (128).  Most of the Senegalese workforce (80%) labors in 
the agricultural sector.  The major commodities produced are the groundnut (principal 
cash crop), millet, sorghum, rice, maize, and peas.  
 In January 1994, Senegal undertook a bold economic reform, which began with a 
50% devaluation of the Senegalese currency, the CFA franc.  Government price controls 
and subsidies were progressively eliminated and real growth in GDP rose from 2% in 
1993 to an average of 5% annually from 1995 to date.  Since the beginning of the 
implementation of the reform plan, annual inflation has been reduced to 2% and the fiscal 
deficit has also decreased to about 1.5% of GDP.  Senegal has also achieved full Internet 
connectivity in 1996, an achievement that has led to the burgeoning of information 
technology-based services in the private sector (106, 128). 
Despite these advances and improvements in the economy, Senegal remains a 
poor country with rising unemployment rates (40% among the urban youth), with 26.3% 
of the population living on less than one dollar a day and 68% living on less than two 
dollars a day.  Only 32% of households have electricity and only 49% have running water 
(106, 128). 
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Chapter 4: Research Objectives 
 
1. Summary of the problem
The prevalence of anemia among pregnant women in Senegal is at least as high as 50%.  
Anemia has multiple causes and increases the risk of adverse pregnancy outcomes.  As 
the current strategy to combat anemia among pregnant Senegalese women stands, when 
women visit public health centers for prenatal care, they are examined by the center 
midwives (e.g. height, weight, height of fundus, and blood pressure are measured, stage 
of gestation is estimated, symptoms and complaints are recorded) who then give them a 
written prescription to purchase iron/folic acid tablets at the health center pharmacy.  
Each tablet contains 65 mg elemental iron (200 mg ferrous sulfate) and 250 µg folic acid 
and is to be taken once daily.  Women are instructed to purchase enough tablets for daily 
supplementation until term.  Studies show that these types of programs are generally less 
effective than desired mainly because of low compliance.  Low compliance is strongly 
related to the following factors: 1) limited knowledge of women about anemia and the 
utility of tablets, 2) erroneous beliefs and fears about iron tablets, 3) health care workers’ 
inadequate knowledge and counseling of pregnant women, 4) the occurrence of 
gastrointestinal side effects with high doses of iron, 5) limited resources for women to 
purchase supplements, 6) hindered access of women to supplements (e.g. health center 
pharmacies may often run out of stock); another important barrier to program 
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effectiveness is the fact that iron supplements alone cannot effectively treat anemia if 
other important underlying causes of the disease coexist with iron deficiency.   
 
2. Objectives
The main objective of this study was to evaluate and, if necessary, provide a framework 
for recommendations for the improvement of the supplementation program for pregnant 
women in Senegal.   First, we wanted to determine the prevalence and major risk factors 
for anemia in this population in order to ascertain whether iron/folic acid tablets alone 
constitute an effective treatment of anemia.  Next, we hypothesized that if pregnant 
women attending health centers were given free iron/folic acid tablets during the prenatal 
visit instead of a prescription to purchase them, some potential barriers to program 
success would be eliminated, including the inadequacy of tablet supply at the designated 
health center pharmacy and the lack of financial resources for women to purchase the 
supplements.  In addition, giving the supplements during the visit could encourage 
midwives to explain their utility and allay possible misgivings that patients have about 
the tablets (e.g. that iron supplements will make their infant « big » and therefore difficult 
to deliver).  At the health center pharmacy, midwives have no control or final input into 
what is communicated to patients.  The net effect of the elimination of these barriers 
could be an increase in compliance with supplementation.  Lastly, we wanted to 
determine the factors that influence compliance because understanding these factors in 
this population can be the basis of recommendations to improve patient care and 
counseling.   
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Chapter 5:  Materials and Methods 
 
1. Subjects
The study was conducted in the capital city of Senegal, Dakar.  It is subdivided 
into 8 health districts, that each represents a different geographical area, and counts 11 
health centers.  Subjects were recruited from the 6 “reference” health centers, which are 
larger than the others and offer more services, such as surgery and radiography.  Two of 
the selected health centers are located in the South health district; the remaining 4 are 
each located in the Center, West, Pikine, and Guediawaye health districts.  Pikine and 
Guediawaye are located in the suburban area of the city.  The selected health centers each 
cover a population of about 180,000 (127). 
All women who registered for routine prenatal care and who fulfilled the following 
criteria were invited to participate in the study after giving informed consent: 1) residing 
in Dakar or its suburbs, 2) not having used iron/folic acid supplements prior to 
enrollment, 3) being at the beginning of the second trimester of gestation as estimated by 
fundal height and date of last menstrual period, 4) and being apparently healthy.   We 
chose to recruit women in their second trimester of gestation because we needed to 
maximize the duration of intervention, because iron needs are highest during the second 
trimester of gestation; and because most women do not seek prenatal care before this 
stage of gestation (106).  This study was reviewed and approved by the Committee on 
Ethics of the Senegalese Ministry of Health and the Institutional Review Board of the 




To avoid bias, we chose to randomize the health centers instead of the subjects 
themselves.  Health centers were randomly assigned to either the control or intervention 
group by a computerized random digit generator.  Assignment was as follows: 
Control Group Intervention Group
Institute of Social Hygiene  
Philippe Senghor  
Roi Baudouin  
Center for Maternal and Infant Protection  
Gaspard Kamara  
Dominique  
 
Women at the control centers received routine prenatal care such as devised by national 
policy.  At the end of their visit, they received a prescription to purchase enough iron/ 
folic acid tablets [65 mg elemental iron as 200 mg dried ferrous sulfate + 250 µg folic 
acid)] at the health center pharmacy for daily supplementation until their next prenatal 
visit.  At follow-up visit, the prescription was renewed until term.   
Women at the intervention centers underwent the same prenatal treatment regime as 
women in the control group, except that at the end of their visit, the midwives gave them 
enough free iron/folic acid tablets for daily supplementation until term.  The free tablets 
had the same appearance and composition as those prescribed for women in the control 
group.  They were pre-packaged in plastic bags and women were asked not to discard 
empty tablet packages.  The iron/folic acid tablets are provided to Senegal by the United 
Nations International Children’s Fund (UNICEF) through the Poverty Reduction Funds. 
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2.2 Anthropometric measurements 
Weight was measured to the nearest 0.1 kg on a calibrated beam balance scale.  Height 
was measured to the nearest 0.1 cm with a stationary height board or measuring tape 
affixed to the wall. 
 
2.3 Hematological measurements 
Two venous blood samples were collected from each subject: one in an EDTA-
treated vacutainer tube and another in an evacuated non-treated tube.  The samples were 
packaged in dry ice for transport to the laboratory where analyses were performed. 
Anemia status was assessed by measuring hemoglobin (Hb) concentration using 
the HemoCue photometer (HemoCue, Angelhölm, Sweden); each sample was analyzed 
in duplicate and calibration of the photometer was checked daily using the control cuvette 
provided by the manufacturer.  Anemia was defined according to WHO guidelines as Hb 
< 110 g/L, moderate to severe anemia as Hb <90 g/L, and severe anemia as Hb< 70 g/L.  
Where appropriate, the CDC cut-off values were used to account for hemodilution: Hb < 
105 g/L in the second trimester and a Hb < 110 g/L in the third trimester of gestation (63, 
64). 
Iron status was assessed by measuring erythrocyte protoporphyrin (EP), serum ferritin 
(SF), and serum transferrin receptors concentration (Tfr).  EP was measured with a front-
face hematofluorometer (Aviv Biomedical, Lakewood, NJ) in duplicate.  Calibration of 
the device was checked daily using control solutions provided by the manufacturer.  EP 
concentration was used as an indicator of iron-deficient erythropoiesis.  Values indicative 
of iron deficiency were defined as EP >70 µmol/mol heme (129).  Blood collected from 
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the evacuated tubes was used for SF analysis.  The blood was centrifuged (481 x g, 8 
min, 28ºC).  The resulting serum was then frozen at -20 ºC.  Later, it was thawed in a 
refrigerator (2-8ºC) for no longer than 12 hours before being analyzed by enzyme-linked 
immunosorbent assay with (ELISA) monoclonal antibodies using a kit and the Mini-
Vidas (Biomerieux, France).  An SF concentration <15 µg/L was indicative of depleted 
iron stores (130).  Tfr was measured by ELISA in duplicate using a kit (Ramco 
Laboratories, Inc, Houston).  A best-fit straight line was generated by regression using 
the standards provided by the manufacturer.  A Tfr concentration >8.3 µg/L was 
indicative of iron-deficient erythropoiesis (131).   
Hb, EP, SF, and Tfr concentrations were measured at enrollment and 20 weeks later.   
 
2.4 Malaria parasitemia 
Thick and thin blood films were collected, fixed, and stained with Giemsa buffer solution 
to detect all species of plasmodium parasites.  Malaria parasites were counted as a ratio to 
leukocytes by an experienced parasitologist.  The calculation of parasite density was 
based on 8000 leukocytes per µL of blood.  Densities >5,000 parasites/µL blood were 
considered evidence of clinical malaria (132). 
2.5 Helminth infection 
Study participants were asked to produce a stool specimen in containers provided by the 
researchers on the morning of their visit.  When they were unable to do so, they were 
asked to try again that evening or the following morning and to return the sample to the 
health center.  The samples were conserved in 5% formaldehyde solution until analyses 
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could be performed.  They were stained using the Kato Katz method and read within one 
hour of staining by a trained microscopist for presence of intestinal parasites (133-134). 
 
2.6 C-Reactive Protein 
C-reactive protein (CRP) was measured from the serum at enrollment as an indicator of 
infection or inflammation, which can affect Hb, EP, and SF concentrations, by latex-
enhanced immunonephelometry on a BN II Analyzer (Dade Behring, Newark, DE).  A 
cutoff value of > 6 mg/L was used (135). 
 
2.7 Hemoglobin S 
Blood samples were screened for Hb S within a few hours of collection at enrollment 
using the sodium metabisulfite reduction test.  All samples that were positive for Hb S 
were re-analyzed by hemoglobin electrophoresis of a red blood cell hemolysate on 
cellulose acetate plates to confirm the phenotype (136). 
2.8 Dietary evaluation 
A modified non-quantitative food frequency questionnaire (FFQ) was used to estimate 
dietary intake of iron (Fe) (see appendix A).  The 45-item FFQ was constructed after 
reviewing the food list of the Worldfood Dietary Assessment System (WDAS), which 
was developed at the University of California at Berkeley in collaboration with the Food 
and Agriculture Organization; it is designed primarily for dietary research projects in 
developing countries.  The database contains a list of 1800 foods reported from 6 
countries, including Senegal.  The nutrient composition of foods that were reported as 
frequently consumed in that country was reviewed using the International Minilist (IML) 
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food composition table, which is built into the WDAS.  For each food on the IML, there 
are values for 52 constituents: the data are taken from published food composition tables 
or imputed where no analytic data are available (137).  Foods were included in the FFQ if 
they contribute significant amounts of Fe in the Senegalese diet, or are non-heme Fe 
absorption enhancers (due to their high content of ascorbic acid and citric acid), or are 
non-heme Fe absorption inhibitors (due to their high content of phytate, calcium, 
polyphenols, and tannins).  For intake of heme-Fe, only foods of animal origin were 
included.  For non-heme Fe intake, only plant foods containing >0.35 mg Fe per serving 
were included.  For example, foods were considered important contributors of vitamin C 
if they contain >24 mg of vitamin C per serving.  Foods rich in phytate, tannins, and 
calcium were identified on the basis of the IML and published values.   
Study participants were asked to indicate how often they consumed each item on the FFQ 
over the 12-month period preceding the interview.    
 
2.9 Socio-demographic and health questionnaires 
Women were interviewed at enrollment using structured questionnaires that were pre-
tested on 10 non-study participants at each center for face validity and the necessary 
changes were made prior to data collection.  Characteristics such as age, education level, 
employment status, and household possessions were collected.  Data on parity, known 
diagnosis of disease, and general perception of health were also collected.  
2.10 Assessment of compliance and of factors that affect compliance 
Compliance was on average 20 weeks after the date of enrollment.  Women were 
contacted by telephone and given appointments to return to the health center where they 
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had originally registered for prenatal care.  This mean of communication was chosen 
because most women could not provide an exact street address, as is common in low-
income areas of Dakar.  They were asked to provide a phone number where they could be 
reached; it could be their home or cellular phone number, their husband’s cellular phone 
number or neighbors’ and relatives’.  Ninety seven percent of women in the study sample 
provided a phone number where they could be reached.  On average, three attempts were 
made to contact the participants; once they were reached, they were given an appointment 
date and time to return to the health center for follow-up. For women who did not come 
to their first appointment, two subsequent attempts were made to schedule another 
appointment if needed. 
During the follow-up visit, women in the control group were interviewed to determine the 
number of iron/folic acid tablets they had purchased since their first prenatal visit and the 
number of tablets that remained in their supply.  In addition, women were asked whether 
they had actually ingested the missing tablets to ensure that the tablets had not been given 
away to friends or relatives or lost.  Compliance in this group was then calculated as: 
(Number of tablets ingested ÷ Number of days elapsed since enrollment x 100).  It was 
assumed that the number of days that had elapsed between enrollment and follow-up 
corresponded to the number of tablets that the patient should have ingested. 
Women in the intervention group were asked to bring the bag of supplements they were 
given at enrollment, including the empty tablet packages.  The number of tablets left in 
the bag was determined and women were questioned about actual tablet ingestion.  
Compliance was calculated using the same formula as for the control group. 
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During the follow-up visit, each subject’s compliance was computed and classified as 
either “low compliance”, i.e. < 70% or “high compliance”, i.e.≥ 70%.  This classification 
was chosen on the basis of WHO’s recommendation stating that in countries where the 
prevalence of anemia among pregnant women is ≥40% that supplementation be given for 
6 months (24 weeks) of pregnancy, i.e. 168 tablets (103).  For this study, participants 
were monitored over an average period of 20 weeks during which the maximum number 
of tablets they could have ingested as prescribed would have been 140; 70% of 140 is 98 
tablets, which is 83% of WHO recommended number.  The remaining 28 tablets that 
women would have consumed if monitoring was continued over the full 24 weeks would 
account for about 100% compliance. 
 An in-depth interview, which lasted 20 minutes on average, was then conducted with 
each subject.  Women with low compliance were asked to identify the reason or reasons 
why they did not take the iron/folic acid tablets as directed most of the time.  Women 
with high compliance were asked to identify the factor or factors that motivated them to 
take the tablets as directed most of the time.  All interviews were conducted in the major 
local language of Senegal, Wolof.  The questions were open-ended and were asked in a 
non-threatening or accusatory manner.  Women’s answers were recorded and then 
transcribed word for word by the interviewer.  For example, women in the study sample 
often refer to anemia as “lacking blood”; if a woman answered “I took the tablets because 
I thought they would increase my blood”, the interviewer wrote down the exact phrase.  
The translation and interpretation was done during data entry and analysis.  Where 
women identified more than one factor that influenced their compliance, all factors were 
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recorded; however they were asked to identify what they thought to be the strongest 
factor. 
 
3. Sample size and power analyses
The primary outcome for this study was the prevalence of anemia after 20 weeks of 
supplementation; i.e. the proportions of women in the control and intervention groups 
with below normal Hb concentration at follow-up.  Thus, on the basis of two independent 
samples with a two-sided chi-square test with continuity correction, a significance level 
of .05, and a β-error specification of 0.20, 183 subjects were needed per group (control 
and intervention) in order to detect a 15% relative difference between the 2 groups in the 
prevalence at follow-up.  A total of 480 subjects were recruited (30% more than needed) 
to account for potential loss of subjects. 
 
4. Statistical analysis
All data were coded where appropriate and analyzed using SPSS (version 15.0).  The 
statistical analyses that were performed are explained in detail in the next chapters.  
Briefly, the primary outcomes of this study were comparisons at follow-up, between the 
control and intervention groups, of: 1) compliance, 2) the prevalence of anemia and iron 
deficiency, and 3) mean Hb, EP, and SF.  Other outcomes included the risk factors for 
anemia and the factors that influence compliance.  Statistical significance for all tests was 
accepted at P < .05. 
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Chapter 6:  Results 
 
1. Iron deficiency is a major risk factor for anemia among pregnant women in Senegal
Abstract
Anemia during pregnancy is major public health problem in Senegal.  For effective 
intervention, its causes must be known.  We determined the prevalence of anemia and the 
relative contribution of various risk factors in a cohort of 480 women visiting health 
centers in Dakar.  Hemoglobin (Hb), erythrocyte protoporphyrin (EP), serum ferritin 
(SF), serum transferrin receptors (Tfr) malaria parasitemia, helminthes infection, Hb 
phenotype, and dietary iron intake were assessed.  Overall, 39% of women were anemic 
(Hb<110 g/L), 71% were iron deficient (EP>70µmol/mol heme, SF<15µg/L, or Tfr>8.3 
µg/L), and 34% had iron deficiency anemia.  Twelve percent were infected with P. 
falciparum; 21% had intestinal helminthes, most of which resided in the suburban areas 
of the city.  About 7% had sickle cell trait (Hb AS).  Women consumed heme-iron 
containing foods more frequently than non-heme iron containing foods; however, they 
also consumed iron absorption inhibitors at a high frequency.  Iron deficiency 
>quadrupled the risk of anemia.  Malaria parasitemia and Hb AS significantly increased 
the risk of anemia.  Our findings indicate that for effective control of anemia during 
pregnancy in Senegal, iron supplementation is needed in addition to education of women 
about better food choices.  Antimalarial chemoprophylaxis should be made available to 





Anemia of pregnancy is highly prevalent in Senegal (West Africa).  Although no 
recent survey has been conducted, it is estimated that >50% of pregnant women in that 
country are anemic (1-2).  Anemia, specifically iron deficiency anemia early in 
pregnancy, has adverse consequences on pregnancy outcome, including low birth weight, 
preterm birth, and small-for-gestational age, which are the strongest predictors of 
perinatal mortality; in severe cases, anemia increases the risk of maternal death at the 
time of delivery (3-7).  In Senegal the prevalence of low birth weight is at least 15%; 
maternal and infant mortality rates are high at 560/100,000 and 58/1,000, respectively.  
The proportions of these rates attributable to anemia are unknown; however, studies 
suggest that they are significant (8). 
There are multiple causes of anemia in tropical developing countries such as 
Senegal.  More than half of the cases are generally due to dietary iron deficiency often 
resulting from a diet poor in bioavailable iron but rich in iron-absorption inhibitors such 
as phytates in cereals and polyphenols in coffee and tea.  In addition, nutritional 
deficiencies of folate, vitamin B12, and vitamin A can also cause anemia.  Other 
coexisting causes include malaria parasitemia, intestinal parasite infections and to a lesser 
extent hemoglobinopathies such as sickle cell (Hb S) (9-10).   
As part of its new national health strategic plan the government of Senegal has 
taken steps to improve maternal health, including reducing anemia.  Since >80% of 
women aged 20-34 years seek prenatal care and that the majority of those (83%) obtain it  
in the government-run health centers, improvement efforts have mainly been 
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concentrated on these centers (11).  The government’s program to reduce anemia can be 
summarized as follows: when women go to their first prenatal visit, they are given a 
prescription to purchase iron/folic acid tablets (65 mg elemental iron and 250 µg folic 
acid) and malaria chemoprophylaxis.  The efficacy, effectiveness, and cost-effectiveness 
of this program, which has been in place for the past twenty years, are not known 
although maternal mortality rate has decreased from 1200 to 560/100,000 live births 
between 1990 and 2005 (11).   
An effective program to combat anemia should address all the major causes of 
anemia.  One of the first steps in designing such a program for a specific country is to 
investigate the contribution of each of the known causes of anemia in that country.  Thus 
the purpose of this study was to determine the prevalence and major risk factors for 
anemia in a cohort of pregnant women in urban Senegal and more specifically the relative 
contributions of iron status, malaria parasitemia, helminthes infection, and Hb S to 




The study was conducted in the capital city, Dakar, which is home to 80% of the urban 
population of Senegal.  The country’s fertility rate results in approximately 450,000 
pregnancies annually (11).   
Dakar is subdivided into 8 health districts, which have a total of 11 health centers.  Each 
district represents a different geographical area.  Subjects were recruited from the 6 
“reference” health centers, which are larger than the others and offer more services, such 
as surgery and radiography.  Two of the selected health centers were located in the South 
68
health district; the remaining 4 were each located in the Center, West, Pikine, and 
Guediawaye health districts.  Each health center covers a population of about 180,000 
(12). 
The subjects were participating in a randomized intervention trial of the effect of free 
iron/folic acid tablets versus a prescription to purchase the tablets on compliance.  All 
women who registered for routine prenatal care and fulfilled the following inclusion 
criteria were invited to participate after giving informed consent: 1) healthy according to 
physical examination, 2) in their second trimester of gestation according to fundal height 
and date of the last menstrual period (this criterion was included, in part, because 69.5% 
of  women in Dakar do not seek prenatal care before this stage of gestation (11)), 3) 
residing in Dakar or its suburbs, and 4) not having received iron/folic acid supplements 
prior to enrollment.  For adequate statistical power in the randomized study, 480 subjects 
were enrolled, i.e. 80 women per center. 
 
Socio-demographic, socio-economic and health survey 
 
Women were interviewed at enrollment using structured questionnaires that were pre-
tested on 10 non-study participants at each center for face validity and the necessary 
changes were made prior to data collection.  Characteristics such as age, education level, 
employment status, and household possessions were collected.  Data on parity, known 
diagnosis of disease, and general perception of health were also collected.  Weight was 
measured to the nearest 0.1 kg on a calibrated beam balance scale.  Height was measured 
to the nearest 0.1 cm with a stationary height board affixed to the wall. 
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Anemia, iron, and infection status 
 
Two venous blood samples were collected from each subject: one in an EDTA-
treated vacutainer tube and another in an evacuated non-treated tube.  The samples were 
packaged in dry ice for transport to the laboratory where analyses were performed. 
Anemia status was assessed by measuring hemoglobin (Hb) concentration using 
the HemoCue photometer (HemoCue, Angelhölm, Sweden); each sample was analyzed 
in duplicate and calibration of the photometer was checked daily using the control cuvette 
provided by the manufacturer.  The Pearson correlation between the 2 Hb measurements 
was .998 (P<.001).  Anemia was defined according to WHO guidelines as Hb < 110 g/L, 
moderate to severe anemia as Hb <90 g/L, and severe anemia as Hb< 80 g/L.  This last 
cut-off was used instead of the traditional <70 g/L because only a few women (n =14) 
had Hb concentrations that low (13). 
Iron status was assessed according to two indicators, erythrocyte protoporphyrin 
(EP) serum ferritin (SF), and serum transferrin receptors (Tfr).  EP was measured in 
duplicate with a front-face hematofluorometer (Aviv Biomedical, Lakewood, NJ).  
Calibration of the hematofluorometer was checked daily using control solutions provided 
by the manufacturer.  The Pearson correlation between the 2 EP measurements was .997 
(P<.001).  EP concentration was used as an indicator of Fe-deficient erythropoiesis.  
Values indicative of iron deficiency (ID) were defined as EP >70 µmol/mol heme (14).  
Blood collected from the evacuated tubes was used for SF analysis.  The blood was 
centrifuged (481 x g, 8 min, 28ºC).  The resulting serum was then frozen at -20 ºC.  Later, 
it was thawed in a refrigerator (2-8ºC) for no longer than 12 hours before being analyzed 
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by enzyme-linked immunosorbent assay (ELISA) with monoclonal antibodies using a kit 
and the Mini-Vidas (Biomerieux, France).  An SF concentration <15 µg/L was indicative 
of depleted iron stores (14).  Tfr was measured by ELISA (Ramco laboratories, Inc, 
Houston).  A best-fit straight line was generated by regression using the standards 
provided by the manufacturer.  A Tfr concentration >8.3 µg/L was indicative of iron-
deficient erythropoiesis 
Iron deficiency anemia (IDA) was defined as Hb<110 g/L and EP>70 µmol/mol heme or 
SF <15 µg/L or Tfr>8.3 µg/L. 
C-reactive protein (CRP) was measured from the serum as an indicator of 
infection or inflammation, which can affect Hb, EP, and SF concentrations, by latex-
enhanced immunonephelometry on a BN II Analyzer (Dade Behring, Newark, DE).  A 
cutoff value of > 6 mg/L was used (15). 
 
Malaria and intestinal parasitic infection 
Thick and thin blood films were collected and fixed and stained with Giemsa to detect 
malaria parasitemia.  Malaria parasites were counted as a ratio to leukocytes by an 
experienced parasitologist.  The calculation of parasite density was based on 8000 
leukocytes per µL of blood and all species were identified as P. falciparum. Densities 
>5,000 parasites/µL blood were considered evidence of clinical malaria (16). 
To assess helminthes infection, women were asked to produce a stool specimen in 
containers provided by the researchers on the morning of their visit.  When they were 
unable to do so, they were asked to try again that evening or the following morning and 
to return the sample to the health center.  The samples were conserved in 5% 
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formaldehyde solution until analyses could be performed.  They were stained using the 
Kato Katz method and read within one hour of staining by a trained microscopist for 
presence of intestinal helminthes.  Parasite density was expressed in number of eggs per 
gram of stool (17). 
 
Hemoglobin S 
Blood samples were screened for Hb S within a few hours of collection using the sodium 
metabisulfite reduction test.  All samples that were positive for Hb S were re-analyzed by 
hemoglobin electrophoresis of a red blood cell hemolysate on cellulose acetate plates to 
confirm the phenotype (18). 
 
Dietary evaluation  
A modified non-quantitative food frequency questionnaire (FFQ) was used to estimate 
dietary intake of iron (Fe).  The 45-item FFQ was constructed after reviewing the food 
list of the Worldfood Dietary Assessment System (WDAS), which was developed at the 
University of California at Berkeley in collaboration with the Food and Agriculture 
Organization; it is designed primarily for dietary research projects in developing 
countries.  The database contains a list of 1800 foods reported from 6 countries, including 
Senegal.  The nutrient composition of foods that were reported as frequently consumed in 
that country was reviewed using the International Minilist (IML) food composition table, 
which is built into the WDAS.  For each food on the IML, there are values for 52 
constituents: the data are taken from published food composition tables or imputed where 
no analytic data are available (19).  Foods were included in the FFQ if they contribute 
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significant amounts of Fe in the Senegalese diet, or are non-heme Fe absorption 
enhancers (due to their high content of ascorbic acid and citric acid), or are non-heme Fe 
absorption inhibitors (due to their high content of phytate, calcium, polyphenols, and 
tannins).  For intake of heme-Fe, only foods of animal origin were included.  For non-
heme Fe intake, only plant foods containing >0.35 mg Fe per serving were included.  
Foods were considered important contributors of vitamin C if they contain >24 mg of 
vitamin C per serving.  Foods rich in phytate, tannins, and calcium were identified on the 
basis of the IML and published values.  Study participants were asked to indicate how 
often they consumed each item on the FFQ over the 12-month period preceding the 
interview.    
 
Statistical analysis
Multinomial logistic regression models were performed to estimate the adjusted 
odds ratios (AOR) and 95% confidence intervals (CI) for anemia, iron-deficient 
erythropoiesis, and depleted iron stores.  Since EP, SF, and Tfr were skewed, they were 
log-transformed for analysis.  Adjusted mean differences in Hb, EP, SF, and Tfr were 
calculated with forward selection multiple linear regression.  All regression models 
included variables for malaria parasitemia, intestinal parasite infection, CRP, Hb S, stage 
of gestation, time elapsed between the previous and current pregnancies (birth interval), 
socio-economic, demographic, and anthropometric data.  Variables were retained in the 
models only if statistically significant.  Since the intensities of malaria parasitemia and 
parasitic infection were relatively low in the population that was studied, the data were 
entered as present or absent.   
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Differences in the prevalence of anemia and/or iron deficiency were assessed 
using chi-square for dichotomous variables.  Differences in Hb, EP, and SF 
concentrations were ascertained by Student t test and ANOVA for categorical variables.  
Where appropriate, Dunnett’s C test was used for post-hoc comparisons for samples with 
unequal variance.   
Foods in the FFQ were grouped into 4 categories: sources of heme-Fe, sources of 
non-heme Fe, sources of Fe absorption enhancers, and sources of Fe absorption 
inhibitors.  Mean frequencies of consumption were computed and coded to reflect the 
following 3 categories: almost never/a few times a month, several times a week, and 
several times a day.   
An index of socio-economic status (SES) was created from 4 binary indicators: 
paid employment, home ownership, refrigerator ownership, and literacy.  Subjects were 
assigned a score of 0 to 4 depending on how they scored on each of the indicators.  All 
data were analyzed using SPSS (version 15.0) and statistical significance was defined as 
a P value <0.05.  
 
Results 
Characteristics of the study sample (Table 1) 
The mean age of the sample was 25.7±5.9 years with a range of 15-43 years.  Most 
women were aged between 20 and 29 years (55%).  Only 18% could read and write and 
68% were unemployed.  About 35% were primipares and very few had 5 or more 
children (6%).  For 49% of the non-primipares, the time elapsed between the previous 
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and current pregnancy was of at least 24 months.  Most of the women (81%) had never 
been diagnosed with a serious illness such as HIV/AIDS, diabetes, or cancer; the 
remainder reported diagnoses of chronic heartburn, respiratory disorders, and migraines.  
Most described their current state of health as either good or excellent (51%).  Mean 
weight and height were 60.40±12.7 kg and 1.64±0.6 m, respectively.  Mean SES score 
was 1.6±1.1 on a scale of 4.0 and on average, women spent <$1 per day on food (mean = 
$.99±.98).  Mean stage of gestation at enrollment was 12.4±4.7 weeks. 
 
Prevalence of anemia, iron deficiency, and iron deficiency anemia (Table 2 & 3) 
Overall, 39% of the women were anemic, of which only 7% suffered from severe anemia 
(Hb <80 g/L).  Around 70% were iron deficient; 40% had low SF, 63% had elevated EP, 
and 18.5% had elevated Tfr.   The prevalence of iron deficiency anemia was 34%.   
 
Malaria 
Malaria parasitemia was detected in only 12% of women (n = 433; 47 blood films were 
unreadable at the time of analysis).  P. falciparum was the only species detected.  Mean 
parasite density was low at 342.4±2091.9/µL blood; only 5 women had parasite densities 
indicative of clinical malaria (>5,000/µL blood).  Mean Hb, EP, SF, and Tfr were not 
significantly different between women with and without malaria parasitemia. 
 
Helminth infection 
Parasitic infection was assessed for a sub-sample of 298 women; the remainder of the 
women either did not provide a stool sample or the sample that they provided was 
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deteriorated at the time of analysis.  Overall, only 13% (n = 63) tested positive for 
intestinal helminthes.  Most (82% n = 52) were infected with A. lumbricoides with a 
mean density of 866 (S.E 120.6) eggs/g; 13% (n = 8) were infected with T. trichiura with 
a mean density of 262.5 (76.6) eggs/g.  About 5% (n = 3) were infected with A. 
duodenale with a mean density of 48.0 (13.8) eggs/g.  Sixty two percent of infections 
were found among women who resided around and visited the two suburban health 
centers.  Mean Hb, EP, SF, and Tfr were not significantly different between women with 
and without parasitic infections. 
 
Hb S analysis 
The sodium metabisulfite screening test was performed on 415 subjects (65 samples were 
missing from women who were enrolled in the study before the test was available).  Only 
6.5% tested positive (n = 27) and were all heterozygote for sickle cell trait according to 
cellulose acetate electrophoresis. 
 
Dietary intake of heme and non-heme iron, iron absorption enhancers and 
inhibitors (Table 4) 
 
Approximately 35% of women reported consuming heme-Fe containing foods several 
times a day; 25% consumed non-heme Fe containing foods at that frequency; 34% and 
40% reported consuming foods containing Fe absorption enhancers and foods containing 
Fe absorption inhibitors, respectively, several times a day.  Mean Hb concentration was 
significantly higher among women who consumed Fe inhibitors only several times a 
month as opposed to several times per day (P<.05).  Mean Hb, EP, SF, and  did not differ 
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significantly across frequencies of consumption of heme-Fe, non-heme Fe, Fe enhancers 
and inhibitors; however, there was a general trend of increasing mean Hb and SF with 
increased consumption of heme-Fe, non-heme Fe, and enhancers and decreased 
consumption of inhibitors.  There was also a trend of decreasing EP concentration with 
increased consumption of heme-Fe, non-heme Fe, and enhancers and decreased 
consumption of inhibitors. 
 
Relation of anemia to iron deficiency, malaria parasitemia, parasitic infection, and 
Hb AS  
 
In the multiple logistic regression, the adjusted odds ratio (AOR) of anemia associated 
with the combination of elevated EP and low SF was 4.63 (95% CI 2.05 – 10.41).  The 
AORs for Hb AS, malaria parasitemia, and parasitic infection were 4.01 (95% CI 1.20 – 
13.72), 2.36 (95% CI 1.00 – 5.58), and .923 (95% CI .45 – 1.87).  The association 
between anemia and helminthes infection is not significant since the confidence interval 
includes 1. 
A stepwise multiple linear regression analysis was conducted with forward selection to 
predict Hb concentration from iron status indicators while controlling for various factors:  
Block 1 included: the intensity of parasitic infection, malaria parasitemia, Hb AS, and 
CRP.  Block 2 included: stage of gestation, age, weight, height, and SES score.  Block 3 
included: log EP, log SF, and log Tfr.  The three blocks were so ordered to determine the 
proportion of variation in Hb concentration accounted by the iron status indicators in 
block 3 above and beyond the factors in the remaining blocks.  The first block of 
predictors accounted for a significant amount of Hb variability with an R2 = .042 (P = 
0.014).  The second block, controlling for the first, also accounted for a significant 
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amount of Hb variability, R2 change was .11 (P <.001).  The third block, controlling for 
the first two, accounted for the largest Hb variability with R2 change of .44 (P < 0.001).   
 
Relation of anemia with other factors 
The prevalence of anemia was not associated with age category, parity, birth interval, or 
SES score (Chi-square tests, P>.05).  Neither iron-deficient erythropoiesis nor depleted 
iron stores or the combination of the indicators were associated with the three maternal 
characteristics mentioned above.   
 
Discussion
Anemia among pregnant women is a major public health problem in Senegal.  
This is the first study in recent years to investigate the multiple risk factors for anemia of 
pregnancy among low-income urban women.  This study can provide a framework for 
recommendations for effective prevention and treatment.   
We found that almost 40% of women in a cohort of pregnant women in Dakar 
were anemic.  This prevalence is somewhat lower than WHO estimates of anemia in 
West Africa (20).  It is also lower than previous estimates in Senegal (1-2).  The fact that 
all women in our sample were recruited in the beginning of the second trimester of 
gestation may explain these discrepancies; the stage of gestation at which women were 
sampled to generate the WHO and other data is unclear.  If a large proportion of women 
in those samples were at more advanced stages of gestation, we would expect their 
hemoglobin concentration to be lower because of plasma volume expansion (21).  We 
recruited women at the start of the second trimester for two reasons: 1) it is the stage at 
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which most women go to their first prenatal visit (11) and 2) it is when expansion of 
blood volume begins and when iron needs rise dramatically (21). 
Iron deficiency was very prevalent at 71%; however, serum ferritin concentrations 
were not as low as expected, suggesting that most women did not enter pregnancy with 
depleted iron stores.  Thirty four percent of cases of anemia were attributable to iron 
deficiency.  Iron deficiency more than quadrupled the odds of anemia after controlling for 
other causes; serum ferritin, erythrocyte protoporphyrin, and serum transferrin receptor 
concentrations accounted for 44% of the variability in hemoglobin concentration.  
Analysis of the food frequency questionnaire showed that women consumed heme-iron 
foods more frequently that non-heme iron foods; however their consumption of 
absorption inhibitors was more frequent.  These inhibitors included rice, millet, and 
maize, which contain phytates, which all women consumed at least once a day because 
they are staples in Senegal.  These inhibitors also included a local black tea and coffee 
which contain phenolic compounds and were consumed several times a day by 40% of 
the women.  Our findings indicate that dietary iron, although available to this population, 
is hindered by the consumption of absorption inhibitors.  Furthermore, the 2005 Senegal 
Demographic and Health Survey (DHS) reported that only 7% of mothers of children <5 
years of age are undernourished in Dakar whereas 40% are over-nourished as indicated 
by body mass index (11).  This, again, suggests that inadequate iron intake in this 
population is more related to poor food choices than to the unavailability of food.    
Our findings support the current policy of universal iron/folic acid supplementation for 
pregnant women who visit public health centers for prenatal care.  DHS reports that 95% 
of women in Dakar receive a prescription to purchase supplements at their first prenatal 
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visit; however there is no data available to suggest that women actually purchase the 
tablets and comply with daily supplementation.  Women also need to be educated about 
better food choices so that they consciously increase bioavailable iron intake and 
decrease their intake of absorption inhibitors.  Unfortunately, the DHS survey also 
indicates that only 8% of women in Dakar reported having received nutritional 
counseling at their prenatal visit (11). 
Seventeen percent of women who were tested for helminthes were infected with 
A. lumbricoides, which is a nematode that invades the gastrointestinal tract after 
ingestion of its eggs in contaminated foods or drinks.  A high parasite load can cause iron 
deficiency anemia, especially when dietary iron quality and quantity are marginal, when 
the host’s general nutritional status is poor, and when coexisting infections are present 
(22).  However, we found that the parasite load in the sample was low.  The same was 
true for hookworms.  Mature hookworm infection causes intestinal bleeding leading to 
fecal bleeding and eventually to anemia depending on the worm burden (>2000 
eggs/gram stool) (9).  Only 1% of women were infected with A. duodenale and the worm 
burden was light.  The third parasite that was detected was T. trichiuria, a whipworm, 
which invades the intestinal tract after consumption of contaminated foodstuffs and can 
cause iron deficiency depending on the parasite load (9).  Again, worm burden was low.  
We expected to find a larger prevalence of helminthes infection in this population and 
much heavier worm burdens because an increasing number of people in Dakar consume 
street foods prepared in unsanitary make-shift restaurants.  A survey of the risk of 
parasitic infection among consumers of these foods in Dakar found that 60% and 45% of 
food sellers and consumers in the sample were infected with protozoans (23).   
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Since worm burdens were low for all three parasites, we pooled them as one variable in 
the analysis of risk factors for anemia.  Infection did not increase the odds of anemia.  
WHO recommends that anti-helminth drugs be given prophylactically to pregnant women 
in conjunction with iron/folic acid tablets only in areas where infection is endemic and 
anemia is very prevalent; the combination of therapy and supplementation enhances Hb 
response (24).  Our data does not indicate that this is the case in Dakar although this may 
have been due to the fact that we only obtained stool specimens from 62% of the original 
sample.  However, since the proportion of women who were infected was not negligible 
(21%, n = 298) and since most of those who were infected were recruited from the 
suburban health centers (Pikine and Guediawaye), pregnant women can benefit from a 
routine stool examination, especially in areas where infection rates are higher.  The 
suburban neighborhoods of Dakar are home to many of the low-income migrants who 
come from rural areas of the country where parasitic infections are more prevalent.  They 
often reside in cramped houses where sanitary conditions are poor and conducive to 
helminthes transmission.       
Malaria parasitemia was detected in 12% of women and the only species found 
was P. falciparum. This is consistent with the findings of a survey involving 2,583 
individuals in Dakar where P. falciparum was the only parasite observed in all age groups 
(1 to 80 years).  Infection rates were greatest between October and December, the period 
that immediately follows the rainy season.  The annual incidence of parasitemia in the 
sample was 5% (25).  Women were enrolled in our study between February 2005 and 
March 2006, which covers the period of greatest infection rates.  Although WHO defines 
severe malarial anemia as Hb concentration < 50 g/L in the presence of a normocytic 
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blood film and P. falciparum parasitemia > 10,000 parasites/µL of whole blood, in 
practice, severe malarial anemia is defined at the level of Hb concentration cited above, 
but in the presence of any P. falciparum parasitemia (25).  We found that only 2 women 
in our sample had malarial anemia according to this definition.  Malaria parasitemia more 
than doubled the risk of anemia after controlling for other causes.  Currently, 91% of 
women who visit health centers receive a prescription to purchase antimalarial drugs; 
however, only 8% receive the very effective intermittent preventive treatment (Fansidar) 
during the prenatal visit (11).  As a result of untreated mild forms of malaria in malaria 
endemic areas, adult women become semi-immune to the disease so that many malarial 
infections are asymptomatic.  However, these forms of infection can contribute to mild to 
severe maternal anemia depending on the level of acquired immunity prior to pregnancy 
and the efficacy of immune responses during pregnancy; and this anemia attributable to 
malaria leads to negative perinatal outcomes (26).  Much improvement is therefore 
needed in the delivery of antimalarial chemoprophylaxis in health centers.  
We chose to investigate the Hb variant form that would be most common in the 
population that was studied, Hb S.  In Senegal, the Hb S gene frequency is > 0.02 (27).  
For the homozygous form, Hb SS, the amino acid mutation in Hb causes Hb S to 
aggregate into filaments when deoxygenated.  These filaments are of sufficient size and 
stiffness to give red blood cells an irregular crescent-like shape (or sickled shape) that 
causes vaso-occlusion and their destruction, hence the term sickle cell anemia.  The 
heterozygous state for sickle cell, Hb AS, often results in a milder form of anemia (28).  
We found that 6.5% of the women in our sample had Hb AS, which more than 
quadrupled the risk of anemia.  Careful screening of women should be done at the time of 
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the prenatal visit.  A simple sodium metabisulfite test can be performed.  The test is 
currently performed on only 79% of women who seek prenatal care (11). 
 
Recommendations  
Since iron deficiency was very prevalent in this sample and was the strongest risk 
factor for anemia among the factors studied, we recommend that public health efforts to 
control anemia in Senegal include two phases during the prenatal visit: 1) the education 
of pregnant women about making better food choices to limit the consumption of iron 
absorption inhibitors and 2) an effective iron supplementation program.  The current 
program which consists of writing a prescription for women to purchase supplements has 
not been evaluated. 
 Since helminthes infection was not prevalent and was not a significant risk factor 
for anemia, systematic anthelminthic therapy may not be necessary for this population.  
However, we do recommend that women who reside in areas where the prevalence of 
infection is generally high to undergo stool analysis.  The analysis is available at almost 
all health center laboratories.  A single course of anthelminthic therapy coupled with 
iron/folic acid supplementation can dramatically improve hemoglobin and iron status 
(29).  Malarial chemoprophylaxis should be made available to all pregnant women.  
Efforts should be made to significantly increase the proportion of women who receive the 












































61              121.1 (.5) 
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7 68.0 (1.9)     271.6 (26.5)3 15.9 (3.9) 
1Significantly different from anemia, moderate to severe, & severe anemia, ANOVA, P<.05 
2Significantly different from moderate to severe & severe anemia, ANOVA, P<.05 
3Not significantly different from moderate to severe anemia, ANOVA 
4Significantly different from moderate to severe & severe anemia, ANOVA, P<.05 
5Significantly different from moderate to severe anemia, ANOVA, P<.05
Table 1: Characteristics of the study sample of Senegalese pregnant    
 women 
Table 2: Anemia and iron status indicators in the sample of  
 Senegalese pregnant women 
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1Percent sample (N = 480)
2Mean hemoglobin (g/L) (standard error)
3Mean erythrocyte protoporphyrin (µmol/mol heme) (standard error)
4Mean serum ferritin (µg/L) (standard error)
5Significantly different, Student t test, P<.05
Table 3: Prevalence of iron deficiency in the sample of Senegalese pregnant women
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2. Providing free iron/folic acid tablets improves compliance in pregnant women in 
Senegal
Abstract
Iron (Fe) deficiency and anemia during pregnancy remains highly prevalent in Senegal 
because of low compliance with Fe supplementation. Improving women’s access to 
supplements may increase compliance. Six prenatal centers in Dakar were randomly 
assigned to either a control group in which women received routine prenatal visits, 
including prescriptions to purchase Fe/folic acid tablets (IFA) according to the guidelines 
of the current Senegalese supplementation program (n = 112); or to an intervention group 
in which women received free IFA (n = 109) in addition to routine prenatal care. 
Compliance was assessed 20 weeks after enrollment by pill count and interviews. 
Hemoglobin, erythrocyte protoporphyrin, and serum ferritin were measured at baseline 
and follow-up. Compliance was 48% and 86% in the control and intervention groups, 
respectively (P<.001). After adjustment for confounding, prevalence of anemia was 62% 
among controls versus 31% among interventions (P<.01); prevalence of Fe deficiency 
was 84.5% and 56.9% in the control and intervention groups, respectively (P<.01). 
Improving access to IFA for pregnant women visiting health centers could dramatically 
increase compliance, improve Fe status and decrease the incidence of anemia. 
 
Introduction
Anemia among pregnant women continues to be a major public health problem in 
West Africa.  The World Health Organization (WHO) estimates that it affects 47% of 
women in that region (1).  In Senegal, the prevalence of anemia is estimated at >50% (2-
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4). Anemia during pregnancy and specifically iron deficiency anemia (IDA) during the 
first and second trimesters of gestation has been linked to increased risk of low birth 
weight and preterm delivery, which are the strongest predictors of perinatal mortality.  
Severe anemia during pregnancy also increases the risk of maternal mortality (5-6).  The 
etiology of anemia is often multifold in West Africa; however, more than half of the 
cases are generally due to iron deficiency (ID) (7).  
Iron (Fe) supplementation of pregnant women who visit prenatal care clinics is 
one of the most widely used strategies to combat anemia and IDA in West Africa, 
including in Senegal (8).  In the early 1990’s, the Senegalese Ministry of Health 
implemented a program of universal Fe/folic acid (IFA) supplementation by which 
pregnant women who visit any public health center for prenatal care are given a written 
prescription to purchase tablets containing 65 mg of elemental Fe (200 mg ferrous 
sulphate) and 250 µg of folic acid for the remainder of their pregnancy.  The tablets are 
generally available at the health center pharmacies for a subsidized price of about 1 cent 
for 10 tablets. However, although clinical trials have repeatedly shown that Fe 
supplementation increases pregnant women’s Fe stores and hemoglobin (Hb) 
concentrations (9), this type of community-based supplementation program have 
generally failed to show evidence of improved Fe status in large part due to low 
compliance.  Studies have suggested that among other factors that affect compliance, 
inadequate access, supply, and distribution of supplements are major ones (10-12).   
We hypothesized that if pregnant women attending health centers were given a 
free supply of IFA during the prenatal visit instead of receiving a prescription to purchase 
tablets, i.e. if their access to supplements was improved, compliance would also increase.  
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Thus, the objective of this study was to compare the effectiveness of free IFA versus a 
prescription at increasing compliance, therefore improving Fe status and decreasing the 
prevalence of anemia among pregnant women.    
 
Subjects and methods
Study area and population 
The study was conducted in Dakar, the capital city of Senegal, where 22% of the 
total population and 80% of the urban population resides.  The population rate of growth 
is estimated at 3%, which is fairly high in part due to the high fecundity rate.  Senegalese 
women have on average 6 children over the course of their reproductive years.  Senegal 
has an estimated prevalence of low birth weight of 15%, an infant mortality rate of 
58/1,000, and a maternal mortality rate of 560/100,000.  Eighty seven percent of women 
aged 20-34 years seek antenatal care across Senegal, 98% of women in Dakar do.  Most 
of this care is provided in government-run health centers by midwives.  The centers cater 
mostly to low-income women at a lower cost than hospitals and at a much lower cost than 
private clinics (13).   
For this study we chose the 6 reference centers (Gaspard Kamara, Philippe 
Senghor, Institute of Social Hygiene, Center for Maternal and Infant Protection, 
Dominique, and Roi Baudouin) of the 11 health centers in Dakar, which cover a 
population of about 180,000 individuals each.  The centers are designated as “reference” 
because they are larger than the others, they have hospitalization beds and surgical units, 
and they train future health care workers.  The first 4 centers are located in the inner city 
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and primarily cater to residents around them while the last 2 are located in suburban low-
income areas and cater to residents of those areas.   
Each health center was randomly assigned to either the control group or the intervention 
group using a computerized random number generator.  In the control centers (Philippe 
Senghor, Roi Baudoin, Institute of Social Hygiene), women were offered the routine 
prenatal visit at the end of which a prescription to purchase IFA [200 mg ferrous sulphate 
(65 mg elemental Fe) and 250 µg folic acid] was given.  As is routine, midwives 
instructed women to purchase as many tablets as they could after their first visit and to 
refill the prescription as necessary until their follow-up visit, at which time they were 
given another prescription; the time period between the first visit and the second varied 
depending on the stage of gestation.  In the intervention centers (Gaspard Kamara, 
Dominique, Center for Maternal and Infant Protection), women received the routine 
prenatal visit at the end of which the midwife gave them a free supply of tablets with 
instructions to take one tablet per day until the end of their pregnancy.  These tablets 
were provided by the researchers who purchased them from the National Pharmacy, 
which supplies the same tablets to the health center pharmacies where they are eventually 
purchased by patients.  The tablets are produced in India and provided by the United 
Nations Children’s Fund (UNICEF).  They were pre-packaged in plastic bags; each 
patient was given the number of tablets sufficient until the date of follow-up and was 
asked not to discard empty tablet packages. 
All women who registered for prenatal care and who fulfilled the following criteria were 
invited to participate in the study after giving informed consent: 1) residing in Dakar or in 
its suburbs, 2) not having used IFA supplements prior to enrollment, 3) being at the 
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beginning of the 2nd trimester of gestation (as estimated by fundal height and date of last 
menstrual period), 4) and being apparently healthy.  We started recruitment at a control 
center where we remained until all subjects were enrolled and then moved on to a 
treatment center.  We alternated between control and intervention centers until all 
subjects were enrolled; the average time spent at each center was 8 weeks. 
This study was reviewed and approved by the Committee on Ethics of the Senegalese 




Twenty weeks after enrollment, study participants were contacted by telephone 
for follow-up.  We chose this mean of communication because most women could not 
provide an exact street address, as is common in low-income areas of Dakar.  They were 
asked to provide a phone number where they could be reached, whether it was a home or 
cellular phone number, their husband’s cellular phone number or neighbors’ and 
relatives’ phone numbers.  An average of three attempts was made to contact the 
participants; once they were reached, they were given an appointment date and time to 
return to the health center for follow-up.  For women who did not come to their first 
appointment, two attempts were subsequently made to schedule another appointment if 
needed. 
Women in the intervention group were asked to bring the bag of supplements they were 
given at enrollment, including the empty tablet packages.  The number of tablets left in 
the bag was counted.  In addition, women were asked whether they actually ingested the 
missing tablets; this was to ensure that the tablets had not been given away to friends or 
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relatives or lost.  According to their answers, the “number of tablets ingested” was 
calculated.  Compliance was calculated as (Number of tablets ingested ÷ Number of days 
elapsed since enrollment) x 100. 
At follow-up, women in the control group were asked how many tablets they had 
purchased since they were given the prescription at their first prenatal visit.  They were 
asked how many tablets they had actually ingested and how many tablets remained in 
their supply.  Compliance was calculated as (Number of tablets ingested ÷ Number of 
days elapsed since enrollment) x 100. 
After follow-up, women in both groups were given IFA sufficient for daily 
supplementation until at least 3 months postpartum. 
 
Hemoglobin (Hb), Erythrocyte protoporphyrin (EP), Serum ferritin (SF), Serum 
transferrin receptor (Tfr), and C-reactive protein (CRP) concentrations 
 
Venous blood samples were collected in EDTA-treated vacutainer tubes at 
enrollment then at follow-up, 20 weeks later.  Hb concentration was determined using the 
HemoCue photometer (HemoCue, Angelhölm, Sweden); each sample was analyzed in 
duplicates and calibration of the photometer was checked daily using the control cuvette 
provided by the manufacturer.  Anemia was defined as Hb < 105 g/L in the second 
trimester and Hb < 110 g/L in the third trimester of gestation according to CDC cutoffs 
(14).   
EP was measured, in duplicate, at enrollment and follow-up with a portable front-
face hematofluorometer (Aviv Biomedical, Lakewood, NJ).  Calibration of the 
hematofluorometer was checked daily using control solutions provided by the 
manufacturer.  EP increases when Fe is unavailable for erythropoiesis.  EP values 
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indicative of ID were defined as EP >70 µmol/mol heme, which is the cutoff that has 
been suggested by WHO (15). 
Venous blood was also collected in evacuated non-treated tubes for SF analysis at 
enrollment and follow-up.  After obtaining the blood, the samples were packaged in dry 
ice for transport from the field to a laboratory where they were centrifuged (481 x g, 8 
min, 28ºC).  The resulting serum was then frozen at -20 ºC.  Later, it was thawed in a 
refrigerator (2-8ºC) for 12 hours before being analyzed for SF concentration by enzyme-
linked immunosorbent assay (ELISA) with monoclonal antibodies using a kit and the 
Mini-Vidas (Biomerieux, France).  A SF concentration <15 µg/L was indicative of ID 
(15).  Tfr was measured by ELISA in duplicate (Ramco Laboratories, Inc, Houston).  A 
best-fit straight line was generated by regression using the standards provided by the 
manufacturer.  A Tfr concentration >8.3 µg/L was indicative of iron-deficient 
erythropoiesis (16). 
C-reactive protein (CRP) was measured at enrollment from the serum by latex-
enhanced immunonephelometry on a BN II Analyzer (Dade Behring, Newark, DE).  In 
research studies such as the one proposed here, CRP is widely used as the marker of 
infection; the cutoff value of > 6 mg/L was used to indicate the presence of infection or 
inflammation (17), which can affect Hb, EP, and SF concentrations. 
 
Baseline characteristics 
Structured questionnaires were administered to each subject to gather socio-demographic 
data (such as age, ethnic group, years of education, money spent on food), medical, and 
obstetric history.  The questionnaires were pre-tested for face validity on 10 women in 
each health center and all necessary changes were made prior to actual data collection.   
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Statistical Analysis
We estimated that there would be at least a 15% relative difference in the 
prevalence of anemia between the control and intervention groups at follow-up.  
Therefore, on the basis of two independent samples with a two-sided chi-square test, a 
significance level of 0.05, and a β-error specification of 0.20, 183 subjects were needed 
per group in order to detect a 15% relative difference.  Thirty percent was added in 
anticipation for loss to follow-up. 
The demographic, health, and dietary questionnaires were coded where appropriate and 
analyzed using SPSS (version 15.0; SPSS Inc, Chicago).  To correct data entry errors, we 
checked frequency analyses for all the variables as well as variable ranges.  The primary 
outcomes of this study were the following: 1) comparison of the prevalence of anemia at 
follow-up in the control and intervention groups, 2) comparison of the prevalence of ID 
(EP>70 µmol/mol heme or SF <15µg/L or Tfr>8.3µg/L) at follow-up in the control and 
intervention groups, 3) comparisons of mean Hb, EP, Tfr, and SF in the control and 
intervention groups at follow-up, 4) comparison of compliance between the control and 
intervention regimen groups.  The statistical methods included: chi-square test of 
homogeneity to compare the proportions of anemia and ID, and compliance; and the 
McNemar test was performed separately on the control and intervention groups to assess 
the significance of change in the proportions from baseline to follow-up; Student t test 
and analysis of variance (ANOVA) to compare means, Dunnett’s C test for multiple 
comparisons (for samples of unequal variance), and paired sample t test to test the 
significance of mean differences between baseline and follow-up were also used.  The 
Kruskal-Wallis for k independent-samples test was used to evaluate differences in 
socioeconomic status (i.e. percent literacy, home ownership, and employment) across the 
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6 health centers.  Variables were tested for normality of distribution and where 
appropriate log transformations were used for parametric testing.  Multivariate analysis of 
covariance (MANCOVA) was used to test the confounding effects of maternal age, stage 
of gestation at follow-up, parity, gravida, baseline Hb, EP, SF, Tfr, and CRP to generate 
the adjusted mean Hb, EP, SF, and Tfr mean differences between baseline and follow-up.  




Of the 480 women enrolled at baseline, 221 (46%) completed the study; 112 (47%) in the 
control group and 109 (45%) in the intervention group (Figure 1).  The only differences 
between women who remained in the study and those who were lost to follow-up were in 
maternal age, stage of gestation, and number of years of formal education.  The sample 
size that was needed to detect a 15% relative difference in the prevalence of anemia 
between the two groups was 366 (183 per group); however, we actually found a >30% 
relative difference (results below), which would have required a much smaller sample 
size of 44 per group.  Thus, our analyses were fully powered despite dropout.  The main 
reasons for loss to follow-up in both groups were: not being able to be reached by 
telephone, delivering before the 20-week follow-up appointment, and refusing to come to 
follow-up.  Women with complete data had a significantly higher number of years of 
education and were slightly, but significantly older than women with incomplete data.  
Women with complete data were at a slightly, but significantly less advanced stage of 
gestation (Table 1).   
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Socio-demographic characteristics and hematological status at baseline 
 
Most of the women who had complete data were married (93.5%), 74% were illiterate 
(could not read or write), 56% were unemployed.  Seventy six percent reported never 
having been diagnosed with a major illness, such as HIV/AIDS, cancer, or diabetes (the 
rest of the sample reported conditions such as asthma, chronic heartburn and migraines); 
51% described their state of health at the time of enrollment as either “good” or 
“excellent”. There was no significant difference in mean age, parity, gravida, stage of 
gestation, weight, or height between the control and intervention groups at baseline.  
However, mean Hb concentration in the intervention group was significantly higher 
(Table 1).  The prevalence of anemia and ID (EP >70 µmol/mol heme, SF <15 µg/L, or 
Tfr>8.3µg/L ) at baseline were not significantly different between the two groups. 
Since the unit of randomization in this study was the health center instead of the 
individuals, descriptive characteristics at baseline were compared across the 6 health 
centers to test for large variations between health centers, which could have introduced a 
bias in subsequent analyses.  Mean parity and gravida were significantly higher at one 
control center compared to an intervention center.  Height was significantly higher in one 
intervention center compared to a control center.  The proportions of women employed 
were significantly higher at two control centers compared to an intervention center 
(Table 2).  From this analysis, we concluded that the clustering effect in this study is 
minimal.   
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Compliance and hematological outcome 
 
Compliance was 67.1% (SE 2.3) in the overall sample; 48.5% (2.9) and 86.2% (2.4) in 
the control and intervention groups, respectively (P<0.0001).   
Hematological status and change was analyzed both within and between the control and 
intervention groups at follow-up. 
Within group analysis: paired sample t tests showed that mean Hb significantly 
decreased in the prescription group (control), but increased in the free IFA group 
(intervention) compared to baseline concentrations.  Mean EP significantly increased in 
the control group while decreasing in the intervention group.  Mean Tfr significantly 
increased in the control group; however it did not change significantly in the intervention 
group.  Mean SF decreased in both groups; however the decrease was only significant in 
the control group. We compared the proportions of women who were anemic and those 
who were ID at baseline and follow-up within each group using the McNemar test of the 
significance of change.  At follow-up, the proportion of women with anemia increased 
significantly only within the control group (37% versus 62%; P<0.001).  The proportion 
of women with ID increased significantly from baseline to follow-up in the control group, 
going from 68.5% to 84.5% (P=0.000).  In the intervention group, the proportion of iron 
deficient women decreased significantly from baseline to follow-up, from 69.8% to 
56.9% (P=0.003) (Table 3).   
Between group analysis: Independent Student t tests showed that mean Hb was 
significantly higher in the intervention group compared to the control group after 20 
weeks of supplementation [115.9 (Std. error 2.2) versus 99.8 (2.2); P<0.0001] and mean 
EP was significantly lower in the intervention than in the control group [96.5 (8.5) versus 
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145.3 (9.4); P<0.0001].  Mean SF was higher in the intervention group; however, the 
difference was not significant.  Mean Tfr was not significantly different between the two 
groups.  The proportion of women who were anemic was significantly lower in the free 
IFA group (31% versus 62%; P<0.0001).  The same trend was observed for the 
proportion of women who were ID deficient (84.5% versus 56.9%; P<0.0001) (Table 3).  
To control for confounding, a multivariate analysis of covariance (MANCOVA) was run 
where Hb, EP, Tfr, and SF concentrations at follow-up were entered as dependent 
variables and the following were entered as covariates: Hb, EP, SF, Tfr, and CRP 
concentrations at baseline, stage of gestation at baseline and follow-up, parity, and 
gradiva.  We found that only Hb, EP, SF, Tfr, and CRP at baseline were significant 
covariates (P <0.05).  After adjustment, the mean difference in Hb concentration at 
follow-up between the control and the treatment groups remained significant (P = 0.015) 
as well as the mean difference in EP concentration at follow-up (P = 0.037).   
 
Discussion
To our knowledge, this is the first study that tested the assumption that pregnant 
women’s poor access to iron supplements negatively affects compliance.  We improved 
access to tablets by providing them for free during women’s prenatal visits at health 
centers in Dakar, Senegal.  We found that women who received free IFA had compliance 
of 86% compared to only 48% for women who received prescriptions to purchase tablets.  
The differential in compliance was corroborated by the hematological profiles in each 
group.  The prevalence of ID in the prescription group increased from 68% at baseline to 
84% at follow-up.  In the free IFA group, the prevalence of ID significantly decreased 
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from 70% at baseline to 57% at follow-up.  Furthermore, the prevalence of anemia in the 
prescription group increased from 37 to 62%, but did not significantly change in the free 
IFA group.  As expected, we also found that Hb and SF concentrations were significantly 
higher at follow-up in the free IFA group and EP concentration was significantly lower.  
This analysis was tested for the potentially confounding effects of maternal age, parity, 
gravida, CRP, gestational age at follow-up (this was important since women entered the 
study and were seen for follow-up at different stages of gestation), and most importantly 
baseline Hb, EP, Tfr, and SF concentrations.  After adjustment for significant covariates, 
mean differences remained significant for Hb and EP.  This study did not address the 
issue of “efficacy” of supplementation, which is the “extent to which a specific 
intervention, procedure, regimen, or service produces a beneficial effect under ideal 
conditions” (19-20).  Efficacy of IFA tablets has been demonstrated in many studies 
conducted in West Africa and elsewhere (9, 21).  We wanted to address the issue of 
“effectiveness”, which is defined as “the extent to which a specific intervention, 
procedure, regimen, or service, when deployed in the field, does what it is intended to do 
for a defined population” (20).  Therefore, beyond giving the treatment group free IFA 
tablets, no attempt was made to influence behavior by supervising tablet intake.  We 
wanted to determine whether giving a free supply of IFA instead of a prescription would 
increase compliance and translate into improved Fe status and decreased incidence of 
anemia.   
The overall prevalence of anemia at baseline (30%) was relatively low compared 
to the >50% prevalence that has been reported elsewhere (3-4).  It is unclear at which 
stage of gestation this prevalence was determined, whereas in our study women were just 
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entering the second trimester of gestation when iron needs are not as high as later in 
pregnancy.  The follow-up measurements were performed 20 weeks after enrollment 
when women were only a few weeks from delivery because we wanted to see whether the 
strategy of giving free tablets was beneficial when risk of ID and anemia is highest 
during pregnancy (4).   
The units of randomization to the two supplementation groups in this study were 
the health centers instead of the women because we wanted to minimize bias and 
confounding: we avoided the risk of women in the control and intervention groups 
communicating among themselves or sharing IFA tablets.  Since only 6 centers were 
included in this study, any data analyses at the cluster level would not have had enough 
statistical power; therefore statistical analyses were conducted at the individual level.  
However, we did compare subject characteristics at baseline across health centers to 
ascertain whether there were large differences between the health centers.  The direction 
of the few differences we found suggested that any clustering effect that may have 
introduced bias was minimal.   
We had an unexpectedly high dropout rate >50% mainly due to the fact that the 
population we were studying was highly mobile, making the task of contacting women 
for follow-up visits very difficult.  We had calculated the required sample size to detect a 
15% relative difference in the prevalence of anemia between the groups and then added 
30% to the sample to account for loss to follow-up.  The actual difference in prevalence 
was far greater than 15%, thus the high dropout rate did not affect our primary outcome.  
We were conservative in our estimate of a 15% difference in prevalence because we were 
aware of no studies of this type that have previously been conducted in Senegal.  The 
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high dropout rate did not introduce significant selection bias in this study.  By comparing 
the baseline characteristics of women who remained in the study and those who were 
lost, we found only slight differences in age and stage of gestation.  Hematological status 
(Hb, EP, and SF), socio-demographic characteristics, and pregnancy factors (parity and 
gravida) were not significantly different between the groups.  One possible concern is 
that women who remained in the study had a significantly higher number of years of 
formal education than those who were lost to follow-up, i.e. 4 years versus 2 years; 
however, the fact that the number of years of education was relatively small in both 
groups minimizes bias.  In addition, the two groups were similar in all other aspects of 
socioeconomic status we assessed.  
 
Conclusions 
Increasing access to IFA tablets by providing them for free to pregnant women in Dakar 
during prenatal visits increased compliance and iron/anemia status dramatically.  The 
Senegalese supplementation program could be more effective if women received free 
IFA instead of prescriptions to purchase the tablets.  The effectiveness of 
supplementation programs depends greatly on women’s compliance.  Understanding the 
factors that influence compliance is therefore paramount to designing and implementing 
successful programs.  Data on the factors that influenced compliance of women in this 
study were collected through in-depth interviews with each participant and are presented 
below.   
The Senegalese government’s ability to provide free tablets to women will depend on 
cost.  Even though IFA tablets are provided by UNICEF through the Poverty Reduction 
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Funds, the government does incur operating costs for receiving, warehousing, and 
distributing the tablets to the various health centers, which justifies why pregnant women 
have to pay for the tablets.  It is therefore necessary to conduct cost-benefit analyses to 
determine whether a strategy of free tablets is more beneficial and whether the resources 
allotted to Senegal by UNICEF (i.e. IFA tablets) are being used efficiently.  The cost of 
treating pregnant women for severe anemia (requires large doses of Fe) which occurs 
when IFA tablets are not taken regularly during the course of pregnancy, and the cost of 
managing negative pregnancy outcomes resulting from anemia of pregnancy, such as 
preterm birth, low birth weight, anemia in infancy is most likely much higher than the 
cost of providing free tablets at the prenatal visit.  In a study of the cost-effectiveness of 
iron supplementation on disability adjusted life years (DALY) in 4 sub-regions of the 
world, Baltussen et al (21) estimated that iron supplementation would avert almost 2.5 
million DALYs in African sub-regions with very high adult and child mortality rates.  
The estimation of cost-effectiveness included the costs of health care for pregnant women 
with provision of iron supplements at 4 prenatal visits.  The cost-effectiveness of iron 
supplementation was $30 per DALY averted, which represents < 3 times the GDP per 
capita in the African sub-regions that were studied; this is consistent with the 
Commission on Macroeconomics and Health’s recent definition of interventions that are 
cost-effective.  The lessons learned in Senegal could be applied widely to other sub-
Saharan African countries in the region, which have similar supplementation programs.   
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Figure 1: Participation and loss to follow-up  
 
6 Health centers randomly 
assigned 
3 Health centers 
Prescription (control) 
(n = 240) 
3 Health centers 
Free tablets (Intervention) 
(n = 240) 
Lost to follow-up (n = 128) 
- went out of town/country (n = 17) 
- delivered before 20 wks (n = 18) 
- spontaneous abortion (n = 6) 
- could not be reached (n = 71) 
- did not give blood samples (n = 3) 
- did not want to come to follow-up (n = 12) 
- was too ill to come to follow-up (n = 1) 
Lost to follow-up (n = 131) 
- went out of town/country (n = 12) 
- delivered before 20 wks (n = 3) 
- spontaneous abortion (n = 3) 
- could not be reached (n = 73) 
- did not give blood samples (n = 10) 
- did not want to come to follow-up (n = 27) 
- were too ill to come to follow-up (n = 3) 
Final sample (n = 112) Final sample (n = 109) 
TABLES & FIGURE
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Complete  Incomplete  
All 




(n = 112) 
Free IFA 
(n = 109) 
All 
(n = 259) 
Prescription 
(n = 147) 
 
Free IFA 
(n = 150) 
 
Age (yrs) 26.7 (.4)1 26.6 (.6) 27.3 (.6) 24.4 (.4) 24.3 (.6) 24.4 (.6) 
Gravida (no.) 2.9 (.1) 3.2 (.2) 2.9 (.2) 2.8 (.2) 2.6 (.2) 2.9 (.2) 
Parity (no.) 1.6 (.1) 1.8 (.2) 1.6 (.2) 1.5 (.1) 1.3 (.2) 1.6 (.2) 
Gestation (wks) 11.8 (.3)1 11.8 (.4) 11.8 (.4) 13.3 (.4) 13.6 (.6) 13.0 (.6) 
Weight 60.9 (.9) 60.4 (1.2) 61.4 (1.3) 58.9 (.9) 58.4 (1.3) 59.3 (1.3) 
Height 1.6 (.003) 
 
1.6 (.003) 1.6 (.004) 1.6 (.005) 
 
1.6 (.007) 1.6 (.006) 
[Hb]3 (g/L) 109.1 (1.2) 106.5 (1.9)2 111.8 (1.6) 108.3 (1.6) 109.5 (2.3) 107.0 (1.6) 
[EP]4(µmol/mol)  113.5 (6.4) 117.8 (10.5) 109.1 (7.2) 119.0 (7.9) 99.6 (9.4) 137.6 (12.3) 
[SF]5 (µg/L) 32.9 (2.2) 31.7 (2.9) 34.1 (3.3) 28.1 (2.7) 28.1 (4.1) 28.1 (3.5) 
Formal education 
(yrs) 
4.4 (.3)1 4.2 (.4) 4.7 2.5 (.2) 2.4 (.4) 2.5 (.4) 
% Employed 29.4 32.1 26.6 30.3 22.2 38.3 
Money spent on 
food/day ($) 
.96 (.08) .95 (.08) .99 (07) .97 (.06) .91 (.09) 1.0 (.13) 
1Significantly different from incomplete (Student t test): P<0.05 
2Significantly different from free IFA group (Student t test): P<0.05 
3Hemoglobin concentration  
4Erythrocyte protoporphyrin concentration 
5Serum ferritin concentration 
Table 1: Baseline characteristics of women with complete and incomplete data in 
the study of compliance with iron/folic acid supplementation among pregnant 
women 
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Table 2: Baseline characteristics of pregnant women across 6 control and intervention health centers in the study of
compliance with iron/folic acid supplementation among pregnant women














Age (yrs) 25.6 (1.0) 25.8 (1.0) 27.8 (1.1) 27.6 (.9) 27.8 (.9) 25.6 (.8)
Gravida (no.) 2.7 (.3) 2.7 (.4) 3.9 (.4)1 3.6 (.3)1 2.6 (.3) 2.1 (.3)
Parity (no.) 1.5 (.3) 1.3 (.2) 2.2 (.3)1 2.2 (.3)1 1.3 (.2) 1 (.2)
Stage of Gestation (wks) 11.7 (.5) 11.9 (.8) 11.8 (.6) 11.6 (.9) 12.7 (.6) 11.4 (.5)
Weight (kg) 62.1 (2.5) 59.6 (1.7) 59.1 (1.9) 64.9 (2.6) 58.8 (1.6) 61.6 (2.2)
Height (m) 1.6 (.007) 1.6 (.008) 1.6 (.008) 1.6 (.009) 1.7 (.01)2 1.6 (.01)
Formal education (yrs) 5.0 (.6) 4.0 (.8) 3.7 (.6) 3.7 (.6) 3.8 (.7) 6.3 (.6)
% Employed 43.74 36.85 19.03 41.2 8.83 29.3
Money spent on food/day
($)
1.0 (.9) 1.0 (.1) .8 (.1) 1.1 (.1) .8 (.1) 1.1 (.1)
1Significantly different from center I3: Dunnett’s C P<0.05
2Significantly different from center C2: Dunnett’s C P<0.05
3Significantly different from centers I1 & I3: Kruskal-Wallis P<0.05
4Significantly different from centers I2 & C3: Kruskal-Wallis P<0.05
5Significantly different from center I2: Kruskal-Wallis P<0.05
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Table 3: Hematological status at baseline and follow-up for women in the control 
and intervention groups in the study of compliance with iron/folic acid 
supplementation of pregnant women 
 
Prescription (n = 112) 
 
Free IFA (n = 109) 
 
Hemoglobin (g/L) 
 Concentration at baseline 
 % Anemic2
Concentration after 20 weeks 
 % Anemic3














 Concentration at baseline 
 Concentration after 20 weeks 








Serum ferritin (µg/L) 
 Concentration at baseline 
 Concentration after 20 weeks 








Serum transferrin receptor (µg/L) 
 Concentration at baseline 
 Concentration after 20 weeks 









% Iron deficient at baseline 







2Hemoglobin <105 g/L in 2nd trimester; 3Hemoglobin <110 g/L  
4,5,6,7,8,9Paired sample t test; 4P=.004; 5P=.135; 6P=.004; 7P=.176; 8P=.002; 9P=.144; 10P= .006; 11P=.299 
12,13Significantly different from control group; 11P<.0001; 12P<.0001 
14,15,16,17McNemar test; 14P<.001; 15P=.442; 16P=.001; 17P=.003 
18Erythrocyte protoporphyrin>70µmol/mol heme or serum ferritin<15 µg/L or serum transferrin receptor>8.3 µg/L 
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3. Determinants of compliance with iron supplementation among pregnant women in 
Senegal
Abstract
Community-based iron supplementation programs for pregnant women have lacked 
effectiveness, in large part, because of low compliance.  The objective of this study is to 
determine factors that influence compliance among pregnant women in Senegal.  
Pregnant women (N=221), recruited from 6 health centers in Dakar during their first 
prenatal visit, were randomly assigned to receive either a prescription to purchase 
iron/folic acid tablets (control, n = 112) to be taken daily, according to official policy or 
to receive free tablets (intervention, n = 109).  Compliance was assessed 20 weeks after 
enrollment through interviews and pill count.  Women with low compliance (<70%) and 
those with high compliance (≥70%) were asked to explain what influenced their 
adherence to supplementation.  Overall compliance was 67%; It was significantly higher 
in the intervention than in the control group (86% versus 48%; P<0.0001).  Women with 
high compliance (58%) were motivated by 1) the perception of improved health upon 
taking the tablets (Intervention = 24%; control = 10%), 2) the insistence by midwives that 
they take the tablets, and 3) the mention that the tablets would improve health.  Women 
with low compliance (42%) indicated 1) the experience of side effects that they 
associated with the tablets (Intervention = 13%; control = 14%), 2) misunderstanding that 
they needed to continue taking the tablets throughout pregnancy (intervention = 0%; 
control = 18%), and 3) forgetfulness.  Compliance with Fe/folic acid supplementation in 
Senegal can be increased by improving women’s access to the tablets and by educating 




The World Health Organization (WHO) estimates that anemia affects >47% of 
pregnant women in West Africa and that more than half of the cases are due to iron 
deficiency (ID) (1-2).  In Senegal prevalence of anemia is even higher (>50%) (3-5).   
Anemia has adverse consequences including fatigue, decreased work capacity, and poor 
pregnancy outcomes such as preterm birth, low birth weight, and increased risk of 
maternal death both during delivery and during the postpartum period (6-7). 
To combat ID and anemia, many West African countries, including Senegal, have 
implemented iron (Fe) supplementation programs for pregnant women (8).  However, 
although clinical trials have repeatedly shown the efficacy of supplementation (9), most if 
not all community based programs have not been shown to be effective, i.e. they have not 
decreased the incidence and prevalence of anemia when deployed in the field.  Studies 
conducted in South East Asia, Latin America, and in only a few African countries have 
shown that one of the main reasons why these programs have been less effective than 
anticipated is low compliance of women with taking daily Fe supplements.  Low 
compliance has been associated with a number of factors, including: 1) gastrointestinal 
side effects that can occur with taking Fe, 2) inadequate supply of tablets (including 
limited resources to purchase tablets), 3) inadequate counseling of patients by health care 
providers concerning the utility of tablets and possible transient side effects, 4) poor 
utilization of prenatal health care services, 5) lack of knowledge and/or patient fears 
about the tablets, and 6) community beliefs, attitudes, and practices that affect women’s 
perception regarding tablet use (10-13). 
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In Senegal, all women who seek prenatal care at government-run public health 
centers are given a written prescription by midwives to purchase Fe/folic acid tablets 
(IFA) that contain 65 mg of elemental Fe (200 mg ferrous sulphate) and 250 µg of folic 
acid.  The tablets are sold at the health center pharmacies and cost about 1 US cent per 
tablet.  The supplementation program in Senegal has been in place for nearly two 
decades; however, the overall prevalence of anemia among pregnant women who attend 
prenatal centers has not declined (4).  
The present study is part of a larger study which sought to compare the effectiveness of 
the current Senegalese program to the effectiveness of a modified supplementation 
strategy whereby women would receive a free supply of IFA from the hands of the 
midwives during the prenatal visit instead of a prescription to purchase the tablets from 
the pharmacist.  The hypothesis of the study was that the fact that women receive free 
tablets would eliminate several potential barriers to program success thereby increasing 
compliance.  The results of the randomized controlled trial showed that women who 
received free tablets did indeed have a significantly higher compliance (86%) compared 
to women who received prescriptions (48%) (14).  
The purpose of the present study is to determine and understand the specific factors that 
influence compliance with supplementation among pregnant women in Senegal; such 
understanding is crucial to the design and implementation of a successful and effective 




Study area and population 
The study was conducted in Dakar, the capital of Senegal, home to 22% and 80% 
of the total and urban populations, respectively.  Senegalese women have a high 
fecundity rate of 6 children, which accounts in part for a population rate of growth of 3%.  
Low birth weight is prevalent (15%), infant and maternal mortality rates are high 
(58/1,000 and 560/100,000, respectively).  98% of women aged 20-34 years in Dakar 
seek antenatal care; the vast majority of them seek it in public health centers (15).  This 
care is provided by licensed midwives who receive a three-year training course at 
government-accredited midwifery schools. 
Six reference health centers of the 11 health centers of Dakar, which cover a 
population of about 180,000 individuals each (the vast majority of whom are residents of 
Dakar and its suburbs), were chosen to implement the study.  “Reference” health centers 
are larger than other health centers, they are equipped to provide more sophisticated 
medical care, such as radiography and surgery, and they train future health care workers.  
The randomization procedures used in the larger study are described in detail elsewhere 
(14).  Briefly, the health centers were randomly assigned to either dispense the routine 
prenatal visit services during which a prescription to purchase IFA (65 mg elemental Fe + 
250 µg folic acid) was given to women (control group; n = 3 centers) with instructions to 
purchase as many tablets as they could afford after their first visit, to ingest one tablet per 
day, and to refill the prescription as necessary until their follow-up visit; or to dispense 
the routine prenatal visit during which the midwife gave women a free supply of tablets 
with instructions to take one tablet per day until the end of pregnancy (intervention
group; n = 3 centers).  The tablets were purchased from the National Pharmacy, which 
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supplies the health center pharmacies with tablets of the same appearance and 
composition for sale in pharmacies.  The researchers pre-packaged the tablets in plastic 
bags which contained the number of tablets sufficient until the date of follow-up.  
Women in the intervention group were asked to keep empty tablet packages in the plastic 
bag that was provided. 
All women who registered for prenatal care in the 6 study centers, who had not used Fe 
supplements prior to enrollment, who were at the beginning of the 2nd trimester of 
gestation (as determined by fundal height and date of last menstrual period), and who 
were apparently healthy, were invited to participate in the study after giving informed 
consent.   
This study was reviewed and approved by the Committee on Ethics of the Senegalese 
Ministry of Health and by the Institutional Review Board of the University of Maryland. 
 
Baseline characteristics 
Demographic data (such as age, ethnic background, education) were gathered using 
structured questionnaires.  Medical and obstetric histories were obtained through 
interviews and by consulting patient health center records when available.  For face 
validity, all questionnaires were pre-tested on 10 non-study participants at each health 
center and all necessary changes were made prior to the start of actual data collection. 
 
Compliance 
Compliance was assessed 20 weeks after the date of enrollment.  Women were 
contacted by telephone and given appointments to return to the health center where they 
had originally registered for prenatal care.  This mean of communication was chosen 
because most women could not provide an exact street address, as is common in low-
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income areas of Dakar.  They were asked to provide a phone number where they could be 
reached; it could be their home or cellular phone number, their husband’s cellular phone 
number or neighbors’ and relatives’.  On average, three attempts were made to contact 
the participants; once they were reached, they were given an appointment date and time 
to return to the health center for follow-up. For women who did not come to their first 
appointment, two subsequent attempts were made to schedule another appointment if 
needed. 
During the follow-up visit, women in the control group were interviewed to determine the 
number of IFA they had purchased since their first prenatal visit and the number of 
tablets that remained in their supply.  In addition, women were asked whether they had 
actually ingested the missing tablets to ensure that the tablets had not been given away to 
friends or relatives or lost.  Compliance in this group was then calculated as: (Number of 
tablets ingested ÷ Number of days elapsed since enrollment x 100).  It was assumed that 
the number of days that had elapsed between enrollment and follow-up corresponded to 
the number of tablets that the patient should have ingested. 
Women in the intervention group were asked to bring the bag of supplements they were 
given at enrollment, including the empty tablet packages.  The number of tablets left in 
the bag was determined and women were questioned about actual tablet ingestion.  
Compliance was calculated using the same formula as for the control group. 
During the follow-up visit, each subject’s compliance was computed and classified as 
either “low compliance”, i.e. < 70% or “high compliance”, i.e.≥ 70%.  This classification 
was chosen on the basis of WHO’s recommendation stating that in countries where the 
prevalence of anemia among pregnant women is ≥40% that supplementation be given for 
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6 months (24 weeks) of pregnancy, i.e. 168 tablets (16).  For this study, participants were 
monitored over a period of 20 weeks during which the maximum number of tablets they 
would have ingested as directed would have been 140; 70% of 140 is 98 tablets, which is 
83% of WHO recommended number.  The remaining 28 tablets that women would have 
consumed if monitoring was continued over the full 24 weeks would account for about 
100% compliance. 
 A semi-structured interview, which lasted 20 minutes on average, was then conducted 
with each subject.  Women with low compliance were asked to identify the reason or 
reasons why they did not take the IFA as directed most of the time.  Women with high 
compliance were asked to identify the factor or factors that motivated them to take the 
tablets as directed most of the time.  All interviews were conducted in the major local 
language of Senegal, Wolof.  The questions were open-ended and were asked in a non-
threatening or accusatory manner.  Women’s answers were recorded and then transcribed 
word for word by the interviewer.  For example, women in the study population often 
refer to anemia as “lacking blood”; if a woman answered “I took the tablets because I 
thought they would increase my blood”, the interviewer wrote down the exact phrase.  
The translation and interpretation was done during data entry and analysis.  Where 
women identified more than one factor that influenced their compliance, all factors were 




Hemoglobin (Hb), Erythrocyte protoporphyrin (EP), Serum ferritin (SF), Serum 
transferrin receptors (Tfr), and C-reactive protein (CRP) concentrations 
 
Venous blood samples were collected at enrollment then at follow-up, 20 weeks later.  
Hb concentration was measured with the HemoCue photometer (HemoCue, Angelhölm, 
Sweden).  Anemia was defined as Hb < 105 g/L and < 110 g/L in the second and third 
trimester of gestation, respectively (17).  EP was measured at enrollment and follow-up 
with a portable front-face hematofluorometer (Aviv Biomedical, Lakewood, NJ).  EP >70 
µmol/mol heme, was considered abnormal (18).  Venous blood was also collected for SF 
analysis at enrollment and follow-up.  Serum samples were then obtained and analyzed 
for SF concentration by enzyme-linked immunosorbent assay (ELISA) with monoclonal 
antibodies using a kit and the Mini-Vidas (Biomerieux, France).  An SF concentration 
<15 µg/L was considered abnormal (19).  Tfr was measured by ELISA in duplicate 
(Ramco Laboratories, Inc, Houston).  A best-fit straight line was generated by regression 
using the standards provided by the manufacturer.  A Tfr concentration >8.3 µg/L was 
indicative of iron-deficient erythropoiesis (20).  ID was defined as EP >70 µmol/mol 
heme, SF <15 µg/L, or Tfr >8.3 µg/L. 
 
Statistical Analysis
The questionnaires were coded and the data entered into SPSS (version 15.0; SPSS Inc, 
Chicago).  Each compliance questionnaire was analyzed to determine the key reason why 
the subject had a low or high compliance and that reason was assigned an individual 
code; the frequency distribution of the different reasons were then calculated.  To correct 
data entry errors, frequency analyses for all the variables were checked as well as 
variable ranges.  Student t tests were used to compare means.  Chi-square tests of 
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homogeneity were used to compare compliance between women who received 
prescriptions (control) and women who received free tablets (intervention) and to 
compare the proportions of anemia and ID between the two groups.  To assess the 
significance of change in the proportion of women with anemia and women with ID from 
baseline to follow-up within the two groups, the McNemar test was performed.  




Of the 480 women who participated in the study, 221 (46%) had complete information on 
compliance and were included in the analysis.  The only differences between women who 
remained in the study and those who were lost to follow-up were in maternal age, stage 
of gestation, and number of years of formal education (see previous chapter).  Figure 1 
shows the number of subjects recruited in each center. 
 
Socio-demographic, health, and hematological characteristics  
 
The mean age in the sample was 27±6 years.  Most of the women were married (93.5%), 
57% were illiterate.  Seventy six percent reported never having been diagnosed with a 
major illness, such as HIV/AIDS, cancer, or diabetes (the rest of the sample reported 
illnesses such as asthma, chronic heartburn and migraines); 51% described their state of 
health at the time of enrollment as either “good” or “excellent”. The 2 groups did not 
differ by age, parity, gravida, stage of gestation, weight, or height between the controls 
and the interventions at baseline.  The women had achieved, on average, 4.4 ±4.2 years of 
formal education and 71% were not employed at the time of enrollment (Table 1).  Table 
2 shows the sample’s ethnic distribution.  
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Overall compliance and determinants 
 
Overall, compliance in the control and intervention groups was 67.5% ±29 (n = 221); 
42% of the women had compliance <70% (Mean = 42 ±21; n = 93) and 58% had 
compliance ≥70% (Mean = 88 ±13; n = 128).  Among the compliant, the four main 
reasons for taking the tablets as directed most of the time were: 1) that they perceived a 
health benefit when they took the tablets and therefore continued taking them (i.e. 
alleviation of fatigue and dizziness and improved appetite) (32% of answers), 2) because 
the midwife directed them to take the tablets was a strong motivator to do so (19% of 
answers), 3) because the midwife specifically indicated that the tablets would improve 
their health (13% of answers), and 4) that they always take prescribed medications 
because they are fearful of illness (11% of answers).  About 14% of the women stated 
that they knew that the tablets would “increase their blood” (remedy anemia) or prevent 
them from “losing blood” (prevent anemia), which is what motivated compliance (Table 
3).   
Among women who had low compliance (<70%), the five main reasons why they did not 
take the tablets as directed most of the time were: 1) that they experienced 
gastrointestinal side effects (i.e. one or a combination of nausea, vomiting, diarrhea, and 
constipation) (27% of answers), 2) that the midwife did not explain or they did not 
understand that they needed to purchase more tablets after their first prescription ran out 
(18% of answers) (this answer is only relevant for the control group), 3) that they forgot 
to take the tablets most days (17% of answers), 4) that they could not afford to purchase 
the tablets (13% of answers) (this answer is only relevant for the control group), 5) that 
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they were tired of having to take so many tablets (11% of answers).  In 4% of the cases, 
the midwife should have but did not prescribe the tablets (Table 4). 
 
Compliance and determinants by group assignment 
 
Women who received free IFA (intervention) had a compliance of 86% compared to 
those who received a prescription (control) and had a compliance of 48%, a difference 
that was statistically significant (P <0.0001). 
Control group
Of the 112 women in the control group, 42% had ≥70% compliance (Mean = 88 ±10.5; n 
= 54).  The four main reasons why women took the tablets as directed most of the time 
were: 1) the fact that the midwife directed them to do so (24% of answers), 2) that they 
always take prescribed medications because they are fearful of illness (20% of answers), 
3) that they perceived a health benefit when they took the tablets and therefore continued 
taking them (18% of answers), and 4) the fact that the midwife specifically indicated that 
the tablets would improve their health (17% of answers).  About 10% of the women knew 
that the tablets would “increase their blood” (remedy anemia) or prevent them from 
“losing blood” (prevent anemia), which is what motivated compliance (Table 3).   
Fifty eight percent of women in the control group had < 70% compliance (Mean = 36 
±21; n = 58).  The four main reasons why they did not take the tablets as directed most of 
the time were: 1) that the midwife did not explain or they did not understand that they 
needed to purchase more tablets after their first prescription ran out (28% of answers), 2) 
that they experienced gastrointestinal side effects (22% of answers), 3) that they could 
not afford to purchase their prescription (21% of answers), and 4) that they forgot to take 
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the tablets most days (12% of answers).  In 3% of the cases, the midwife should have but 
did not prescribe the tablets (Table 4). 
Intervention group
Of the 109 women in the intervention group, 68% had ≥70% compliance (Mean = 88 
±15; n = 74).  The three main reasons why women took the tablets as directed most of the 
time were: 1) that they perceived a health benefit when they took the tablets and therefore 
continued taking them (42% of answers), 2) the fact that the midwife directed them to do 
so (15% of answers), 3) the fact that the midwife specifically indicated that the tablets 
would improve their health (11% of answers).  About 18% of the women knew that the 
tablets would “increase their blood” (remedy anemia) or prevent them from “losing 
blood” (prevent anemia), which is what motivated compliance; 8% of the women felt that 
the tablets had to be important since they were given to them during the prenatal visit 
(Table 3).   
Thirty two percent of women in the intervention group had < 70% compliance (Mean = 
51 ±19; n = 35).  The three main reasons why they did not take the tablets as directed 
most of the time were: 1) that they experienced gastrointestinal side effects (34% of 
answers), 2) that they forgot to take the tablets most days (26% of answers), and 3) that 
they grew tired of taking the tablets (23% of answers).  In 19% of cases either the 
midwife did not give the free tablets to the women or the women themselves lost them or 
gave them away to friends and relatives (Table 4). 
 
Prevalence of anemia and ID in the control and intervention groups at follow-up 
 
Twenty weeks after enrollment, the proportion of women with anemia significantly 
increased among women who received a prescription (control) (37% versus 62%; 
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P<0.001), but did not increase significantly among women who received free tablets 
(intervention) (26% versus 31%; P=0.442).  The proportion of women who were Fe 
deficient significantly increased in the control group (68.5% versus 84.5%; P=0.000) but 
decreased in the intervention group (69.8% versus 56.9%; P=0.003) (Table 5).  The 
prevalence of anemia and iron deficiency was significantly higher among women who 
received prescriptions compared to those who received free IFA.  Mean differences in Hb 
and EP concentrations remained significant after control for baseline Hb, EP, SF, Tfr, and 
C-reactive protein, and baseline and follow-up stage of gestation in a multivariate 
analysis of covariance. 
 
Discussion 
This study is the first attempt to understand the factors that influence adherence 
to iron supplementation among pregnant women in Senegal.  It is also one of the few 
studies that examine the specific factors that facilitate high compliance with 
supplementation in a community environment.  The study sample was drawn from six 
different health centers that each cater to a large group of low-income women residing in 
different neighborhoods of Dakar.  The ethnic distribution of the sample is similar to that 
of the general population of Senegal (15).  The sample size was large compared to other 
studies of this kind.   
 Compliance with supplementation in the entire sample was 67%; however, 
women who received IFA during the prenatal visit had significantly higher compliance 
than women who received a prescription, i.e. 86% compared to 46%.  The overall 
compliance of 67% is relatively high compared to compliance previously reported for 
pregnant women in developing countries (11-12, 21-24). 
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In the overall sample, women with the highest compliance (≥70%) were 
motivated by four major factors which accounted for 75% of the responses: 1) the 
perception of improved health upon taking the tablets, 2) the admonishment from 
midwives to take the tablets, 3) the specific mention by midwives that the tablets would 
improve their health, and 4) the fear of becoming ill.   
The first factor in the overall sample was also the single most important motivator among 
women who received free tablets during the prenatal visit (42% of answers) but was only 
the third motivating factor among women who received prescriptions (18% of answers).  
This strongly suggests that dispensing the tablets during the visit increases the likelihood 
that women will start IFA treatment rapidly and will continue long enough to reap health 
benefits, which in turn may motivate them to continue the treatment.  For women who are 
given written prescriptions and directed to purchase the tablets, some barriers may 
prevent or delay them from complying, one of which is financial: a significant proportion 
(21%) of women who had the lowest compliance in the control group indicated that they 
could not afford to purchase their prescriptions.  Furthermore, a significant proportion of 
women in the same group indicated that they did not purchase and take more tablets after 
their first prescription ran out because they did not know that they were supposed to do 
so.  This problem could not have occurred among women who received free tablets since 
they were given a supply for the remainder of their pregnancy; thus, the risk of an 
interruption of treatment in this group was decreased. 
The second and third factors in the overall sample suggest that the quality of counseling 
during the prenatal visit is a very important determinant of compliance.  The combination 
of midwives telling women to take the tablets and of midwives specifically explaining to 
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them that the tablets will improve health accounted for 32% of responses.  Conversely, 
we found that among women who had the lowest compliance, 18% either misunderstood 
the directions given by the midwife or the midwife’s directions were unclear.  Inadequate 
counseling by health care providers has been documented by Galloway et al (11-12) as a 
major barrier to compliance in eight other developing countries and by Oluwatoyin in 
Nigeria (12).  It was the single most important reason for low compliance with 
supplementation as directed (28% of answers) among women who only received 
prescriptions; whereas among women who received free tablets but had low compliance, 
inadequate counseling was not a factor.  Researchers in Mali also found a strong link 
between the quality of counseling by health care providers and compliance. They 
reported that pregnant women complied with supplementation when they were provided 
with “minimum, consistent, and easily understandable information and counseling” (25).  
Results from the current study suggest that giving the tablets to women during the 
prenatal visit may encourage the midwives to clearly explain their purpose; this is further 
supported by the fact that 18% of women who had the highest compliance in the 
intervention group indicated that they took the tablets as directed most of the time 
because they knew their specific function, i.e. they knew that the tablets would either 
prevent them from becoming anemic or would treat their existent anemia.  This 
knowledge was apparent in only 10% of women who received a prescription and had the 
highest compliance.  Adequate verbal counseling is especially important for women with 
little or no formal education.  On average, women in this sample had received only four 
years of formal education and most could not read or write.  In this study, it was assumed 
that midwives at the intervention and control centers dispensed the same overall quality 
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of prenatal care since they all receive the same training at government accredited 
midwifery schools. 
The fourth motivating factor in the overall sample, the fear of becoming ill, cannot be 
tied to specific knowledge about the function of IFA.  Women who evoked it as a factor 
indicated that they generally take any medication they are prescribed.  It accounted for 
20% of answers among women with the highest compliance in the control group but was 
not a major determinant among women with the highest compliance in the intervention 
group.  This may suggest that the specific knowledge of the role of the tablets is a 
stronger motivator than just the fear of illness. 
 In the overall sample, women with the lowest compliance were influenced by 
five factors, which accounted for 81% of responses.  The single most important factor 
was the experience of gastrointestinal side effects (27% of responses).  Side effects have 
traditionally been considered the major obstacle to compliance, leading many to advocate 
weekly instead of daily supplementation; however, more recently, studies have shown 
that side effects have a limited influence on compliance (especially when it is unclear 
how women distinguish the symptoms associated with taking iron tablets and those 
associated with pregnancy) (26).  Findings in this study support this view: despite the fact 
that more women cited gastrointestinal side effects as a major reason for low compliance 
among women who received free tablets than among women who received prescriptions, 
women who received free tablets still had a significantly higher compliance.  This may be 
a further suggestion that adequate counseling is a stronger determinant of whether or not 
women adhere to supplementation.  Midwives should explain to women that Fe tablets 
should be taken with food and that side effects associated with taking the tablets are 
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generally transient.  Although verbal exchanges between the patients and midwives 
during the prenatal visit were not studied, women who received free tablets may have 
received more thorough counseling.   
The second important barrier to compliance, inadequate counseling, was discussed above.  
The third determinant of low compliance was forgetfulness among women with the 
lowest compliance in the overall sample (17%) and both in the control group (12%) and 
the intervention group (26%).  This problem could be addressed through better 
counseling during the prenatal visit by suggesting to women strategies to remember to 
take their tablets; for example, placing the tablets in a spot that they see everyday (e.g. 
breakfast or night table, kitchen counter). 
The fourth barrier was related to the financial inability of women to purchase the tablets; 
this only concerned women who received prescriptions rather than free tablets (21% of 
responses).  In fact, the written prescription that women are given during the prenatal 
visit contains items other than IFA.  The content of the prescription will vary according to 
individual patient afflictions; women who did not purchase the tablets for financial 
reasons generally did not purchase any other medication on the prescription, even though 
the IFAs are affordable (1 cent for 10 tablets).  In addition, among women in the 
intervention group who had the highest compliance, no one indicated that the fact that the 
tablets were provided free of charge was a facilitator of compliance.  The results from 
this study suggest that the benefit of IFA being given during the prenatal visit lies more in 
the fact that it encouraged midwives to explain the purpose of the tablets and less in the 
fact that the tablets were free.   
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The fifth barrier to compliance was expressed by women as being “tired of taking pills”.  
This sentiment was even stronger in women in the intervention group than in women in 
the control group.  Women who expressed this sentiment were further questioned about 
the reason for this “pill fatigue”, but they did not give further details.  This “fatigue” may 
also explain why more women in the intervention group gave away tablets to friends and 
relatives or lost the tablets.  This suggests that daily supplementation is impractical for 
certain individuals who may benefit more from weekly or bi-weekly supplementation.   
 Tablet ingestion was not supervised in this study because our intention was to 
examine the determinants of compliance under usual field conditions.  Calculations of 
compliance were mostly based on the number of tablets that women reported taking in 
the control group and on counting the number of tablets remaining in the bag of tablets 
that were given to women in the intervention group.  However, the finding that women in 
the latter group had significantly higher compliance is supported by the fact that women 
in this group also had a significantly improved Fe status and a lower incidence of anemia 
compared to women in the other group. 
 
Conclusions and recommendations 
Compliance of pregnant women with IFA supplementation in Senegal can be greatly 
improved by increasing women’s access to the supplements.  In this study, access was 
facilitated by asking midwives to hand the tablets to women (free of charge) during the 
prenatal visit, an effort which led to another facilitator of compliance, providing women 
with specific and concise information on the health benefits that the tablets confer.  This 
information should include a mention of possible transient side effects of IFA and 
strategies for women to remember to take the tablets on a daily basis.  Although the fact 
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that the tablets were free facilitated compliance, it was not found to be as important a 
facilitator as proper counseling.  Thus, modifying the Senegalese supplementation 
program to increase compliance may not involve large additional governmental costs.  It 
may just entail a rerouting of the tablet delivery system whereby the tablets would be 
distributed by the very people who are directly involved with delivering care to pregnant 
women, the health center midwives, rather than the health center pharmacists.  However, 
pharmacy workers should also be trained to give appropriate counseling to women 
regarding tablet use.  Since adequate counseling is an important determinant of 
compliance, future inquiries about the effectiveness of IFA supplementation in Senegal 
and other countries should focus on the nature of the interaction between midwives and 




Figure 1 Number of women in the control and intervention groups with complete 
hematological and compliance data 
 
6 Health Centers Randomly 
Assigned 
Philippe Senghor (n = 32) 
Roi Baudoin (n = 42) 
Institute of Social Hygiene (n = 
38) 
3 Control (prescription) centers 3 Treatment (free tablets) centers 
Gaspard Kamara (n = 34) 
Dominique (n = 41) 
Center for Maternal & Infant 
Protection (n = 34)
N = 112 N = 109 
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Ethnic Group Frequency Percent 
n = 221 
Wolof/Lébou 89 40.3 
Poular 56 25.3 
Sérère 34 15.4 
Dioula 11 5 









Mean ±SEM P value1
Age (yrs) 26.7 (.4) 26.6 (.6) 27.3 (.6) .364
Number of yrs of 
formal education
4.4 (.29) 4.2 (.41) 4.7 (.39) .350
% Employed 29.4 32.1 26.6 .3662
$ Spent on food 
daily 
0.97 (.05) 0.95 (.82) 0.99 (.07) .663
Gravida 2.96 (.14) 3.2 (.2) 2.9 (.2) .305
Parity 1.57 (.11) 1.8 (.2) 1.6 (.2) .458
Stage of gestation 
(wks) 
11.8 (.27) 11.8 (.4) 11.8 (.4) .930
Weight (kg) 60.96 (.86) 60.4 (1.2) 61.4 (1.3) .560
Height (m) 1.64 (.003) 1.63 (.003) 1.65 (.004) .158
1 Student’s t test P value of the mean difference between treatment and control groups 
2 Pearson chi-square test of significance 
Table 1 Baseline characteristics of women in the intervention and control groups in 
the study of compliance with iron/folic acid supplementation among pregnant 
Senegalese women 













Frequency % Frequency % Frequency %
Felt better when they ingested 
the tablets 
41 32.0 10 18.5 31 41.8 
Midwife instructed them to 
take the tablets 
24 18.8 13 24.0 11 14.8 
Midwife explained that the 
tablets would improve health 
17 13.3 9 16.6 8 10.8 
Always take whatever they are 
prescribed because of fear of 
illness 
14 10.9 11 20.4 3 4.0 
Knew that the tablets would 
“increase their blood” 
8 6.2 2 3.7 6 8.1 
Were afraid of “losing blood” 6 4.7 1 1.9 5 6.8 
Since the tablets were given to 
them, they felt that it was 
important they take them 
6 4.7 --- --- 6 8.1 
Husband/mother felt that the 
tablets were very important 
for their health and made sure 
they took them 
5 3.9 3 5.6 2 2.6 
Knew that they “lacked 
blood” and that the tablets 
would increase it 
4 3.2 2 3.7 2 2.6 
Thought that the tablets would 
make them feel better 
3 2.2 3 5.6 --- --- 
Table 3 Factors that influenced compliance with supplementation with iron/folic 
acid among Senegalese pregnant women with high compliance (≥70%) in the 
overall sample and in the control and intervention groups 
1N = 221 (Total % may not equal 100 due to rounding) 
2Total number of subjects in control group = 112 













Frequency % Frequency % Frequency %
Experienced gastrointestinal 
side effects 
25 26.8 13 22.5 12 34.2 
Took the tablets until 
prescription ran out; but did 
not purchase more tablets 
because the midwife did not 
say so 
17 18.3 17 29.3 --- --- 
Forgot to take the tablets on 
most days 
16 17.2 6 10.3 9 25.7 
Could not afford to purchase 
the prescription 
12 12.9 12 20.6 --- --- 
Grew tired of taking tablets 11 11.8 3 5.1 8 22.8 
Midwife did not 
prescribe/give the tablets 
(Patient is correct) 
4 4.3 2 3.2 2 5.7 
Lost the prescription/tablets 
but were afraid to ask for 
another  
3 3.2 2 3.2 2 5.7 
Midwife did not prescribe the 
tablets 
(Patient is mistaken) 
2 2.1 2 3.2 --- --- 
Was afraid that too many 
tablets would harm her and/or 
her baby 
1 1.1 --- --- 1 2.8 
Never came to follow-up 
prenatal visits and therefore 
could not get another 
prescription to purchase 
tablets 
1 1.1 1 1.7 --- --- 
Gave away many tablets 1 1.1 --- --- 1 2.8 
Table 4 Factors that influenced compliance with supplementation with iron/folic 
acid among pregnant Senegalese women with low compliance (<70%) in the overall 
sample and in the control and intervention groups 
1N = 221 (Total % may not equal 100 due to rounding) 
2Total number of subjects in control group = 112 
3Total number of subjects in intervention group = 109 
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Control 
n = 112 
Intervention 
n = 109 
% Anemic at baseline1







% Iron deficient at baseline5








1Hb <105 g/L 
2Hb <110 g/L 
3McNemar test (P<0.001); significantly different from intervention group, Chi-square test (P<0.001) 
4McNemar test (P = 0.442) 
5 EP >70µmol/mol heme or SF <15 µg/L or Tfr >8.3µg/L 
6McNemar test (P = 0.001); significantly different from intervention group, Chi-square test (P<0.001) 
7McNemar test (P = 0.003) 
 
Table 5 Prevalence of anemia and iron deficiency at baseline and follow-up among 
pregnant Senegalese women who received a prescription (control) and women who 
received free iron tablets (intervention) 
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Chapter 7: Summary and Conclusions 
 
Despite a national policy of universal iron/folic acid (IFA) supplementation, anemia of 
pregnancy remains a major public health problem in Senegal.  The policy mandates that 
all women who attend public health centers for prenatal care be prescribed to purchase 
and take IFA throughout pregnancy.  However, the effectiveness of this policy may be 
limited by two main factors, low compliance with supplementation and the fact that iron 
and folate deficiencies may not be the only important risk factors for anemia in this 
population such that IFA alone cannot effectively treat anemia.  In this longitudinal study 
we examined a cohort of pregnant women visiting large public health centers in Dakar 
and 1) determined the prevalence of anemia and the relative contribution of several risk 
factors, 2) evaluated the effectiveness of the current national supplementation program by 
determining compliance and comparing it to that of women who received free IFA during 
the prenatal visit, and 3) determined the factors that influence compliance in this 
population.  This is the first study in Senegal to evaluate supplement delivery to pregnant 
women and to provide a framework for recommendations to improve compliance and 
therefore improve iron and anemia status. 
 
Six reference health centers that cater to large low-income population groups in Dakar 
were randomly assigned to either a control group or an intervention group.  In the 3 
control centers, women received routine prenatal care including a prescription to 
purchase IFA.  In the 3 intervention centers, women received routine prenatal care with a 
free supply of IFA during the visit.  At baseline, iron and anemia status were determined 
and the following assessments were made: 1) dietary intake of iron, 2) malaria 
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parasitemia, 3) intestinal parasite infection for a sub-sample of 298 women, and 3) 
hemoglobin phenotyping (Hb S).  Twenty weeks after enrollment (follow-up) 1) 
compliance was assessed in both groups as the ratio of the number of IFA that were 
ingested to the number of days elapsed between enrollment and follow-up, 2) iron and 
anemia status, and 3) the factors that influenced compliance. 
 
Objective #1:
Determining the prevalence of anemia and the relative contribution of various risk 
factors for anemia; this was done to ascertain whether a policy of IFA 
supplementation alone can eradicate anemia of pregnancy. 
 
Findings
Eighty healthy women in their 2nd trimester of gestation were recruited from each center 
for a total of 480.  We found that 39% were anemic, of which 34% had iron deficiency 
anemia.  Twelve percent had P. falciparum malaria parasitemia of which only 1% had 
clinical malaria (>5,000/ µL blood).  Thirteen percent were lightly infected with A. 
lumbricoides, A. duodenale, and T. trichuria. Most of the infected women resided in the 
suburban areas of Dakar.  Six percent had Hb AS.  In a multiple logistic regression, we 
found that iron deficiency was the most important contributor to anemia, more than 
quadrupling the risk of anemia.  Malaria parasitemia and Hb AS also significantly 
increased the risk of anemia.  We also found that women had a higher frequency of 
consumption of heme-iron containing foods (the most bioavailable form) than non-heme 
iron containing foods; however, this was accompanied by a high frequency of 
consumption of iron-absorption inhibitors, such as phytates and polyphenols. 
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Conclusions:
Since iron deficiency was prevalent and was the greatest risk factor for anemia among the 
factors that were studied, a policy of universal IFA supplementation for pregnant women 
is well justified in the context of Senegal.  However, IFA should be accompanied by 
malaria prevention and treatment.  Currently, prenatal care services do include providing 
prescriptions for IFA and antimalarial drugs; however, whether or not women purchase 
and take them as prescribed in unknown and is the focus of the second objective of this 
study.  We recommend that in areas where helminthes infection is prevalent, routine stool 
screening be performed and treatment prescribed when necessary.   A single affordable 
course of treatment after the first trimester of pregnancy cures infection and elevates 
hemoglobin concentration in cases of severe infection.  We also recommend that 
midwives take the opportunity afforded by the prenatal visit to educate women on 
choices of foods available in the market to maximize their iron intake while minimizing 
absorption inhibitors intake. 
 
Objective #2:
Comparing compliance among women who received prescriptions to purchase IFA 
(control) to that of women who were given free IFA during the prenatal visit 
(intervention); this was done in order to ascertain whether the latter mode of 
supplementation is more effective at improving iron and anemia status. 
 
Findings
Two hundred and twenty one women had complete baseline and follow-up data.  We 
found that compliance [(Number of tablets ingested/Time elapsed between enrollment 
and follow-up) x  100] was only 48% in the control group (n = 112) compared to 86% in 
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the intervention group (n = 109).  After adjustment for confounding, the prevalence of 
anemia after 20 weeks of supplementation was significantly higher in the control than in 
the intervention group (62% versus 31%).  The same was true for the prevalence of iron 
deficiency (84% versus 57%). 
 
Conclusion:
Impaired access to IFA has been shown to be one of the major causes of low compliance 
with supplementation in developing countries such as Senegal.  We have shown that by 
increasing access to IFA (i.e. modifying the delivery system of IFA and making them free 
of charge), compliance can be dramatically improved, which translates into much 
improved iron and anemia status.  More than 95% of women who visit public prenatal 
centers do receive a prescription for IFA, but there is no monitoring of whether or not 
women actually purchase and use the supplements.  Our data indicate that a mere 
prescription alone yields relatively low compliance.  The current Senegalese 
supplementation program could be more effective if IFA were provided directly to 
women during the prenatal visit.  Moreover, we need to gain a better understanding of 
what drives the motivation of women to take or not take IFA in order to make more 
precise recommendations for program improvement. 
 
Objective #3:
Assessing the factors that determined high (≥70%) and low (<70%) compliance 




Women who had the highest compliance in the control group were motivated mainly by 
the fact they were told to take the IFA by the midwife; whereas among women who 
received free IFA the chief motivators were the perceived health benefits which they 
associated with taking the tablets and the knowledge of the utility of the tablets (i.e. IFA 
“increase blood”).  Women who had the lowest compliance in the control group cited a 
misunderstanding of instructions given by the midwife about the frequency of intake of 
tablets as being the main reason for non-compliance.  Not being able to afford the tablets 
was only the fourth reason for non-compliance.  Women who had the lowest compliance 
in the intervention group cited the occurrence of gastrointestinal side effects that they 
associated with taking the tablets.  None of them cited misunderstanding midwife 
instructions as a justification for non-compliance. 
 
Conclusions:
Providing women with clear and concise information about the frequency of intake of 
supplements and their utility can dramatically improve compliance.  Achieving this 
necessitates training of health care providers to disseminate this information effectively.  
In addition, dispensing the supplements directly to women during the prenatal visit may 
improve compliance by fostering better communication about the tablets between the 
patient and the midwife.  In the context of the Senegalese national program of 
supplementation, this entails a rerouting of supplements from the pharmacists to the 
midwives; and possibly enhanced midwife training. 
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Implications, recommendations, and future research
This study showed that the prevalence of anemia and iron deficiency is high among 
pregnant women in Senegal.  It also showed that the current policy of prescribing 
pregnant women with iron/folic acid supplements for purchase yields low compliance.  
An alternative distribution policy where women received the actual supplements during 
their prenatal visits improved compliance dramatically.  This improvement was in part 
due to the fact that the supplements were offered free of charge and also to the fact that 
the new distribution strategy fostered better counseling of patients about the utility of the 
tablets.  This was evidenced by the fact that more women in the intervention group knew 
that the tablets would prevent/cure anemia.   
These findings suggest that improving the effectiveness of supplementation in Senegal 
will involve the following: 
1. Changing the distribution flow of supplements: this change can be operated either 
by providing the tablets completely free of charge during the prenatal visit (such 
as was done in this study) or by factoring the price of the supplements in the price 
of the visit.  Both possibilities require a cost analysis.  In the first case this 
analysis would determine whether the government can bare the cost of the tablets.  
In the second case, the analysis would determine whether patients can bare the 
burden of an increased prenatal visit cost.  In either case, the iron/folic acid tablets 
would be dispensed separately from the other drugs that women are prescribed 
routinely at their prenatal visit (e.g. ibuprofen or antimalarial drugs).  In this study 
we found that women who stated that they could not comply with 
supplementation for financial reasons in fact could not afford to purchase their 
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entire prescriptions, not just the iron/folic acid tablets that are purposefully made 
very affordable (1 US cent per 10 tablets).  Furthermore, making the tablets 
available during the prenatal visit allowed women to start treatment sooner than 
those who received prescriptions; the former were therefore able to notice the 
health benefits from the tablets, which encouraged them to continue the treatment.  
Low-income women typically cannot purchase their prescriptions on the same day 
they receive them.  They generally inquire about the total cost of the prescription 
at the pharmacy and then work out a way to purchase it either on their own or 
aided by their husbands or relatives.  This process may take weeks or months if 
they ever succeed to gather enough funds for their purchase.  Thus, treatment is 
delayed or does not occur at all.  
 
2. Training midwives and other prenatal care providers to give women concise and 
precise information about the purpose of iron/folic acid tablets (i.e. the health 
benefits that they provide), the mode and frequency of ingestion, and the 
occurrence of transient side effects should be a public health priority even if the 
supplementation policy is not modified.  This training should involve uniform 
procedures that all midwives at all health centers must follow.  This is to insure 
that all women who go to prenatal visits at any health center receive the same 
quality of counseling.  Improving the quality of counseling may also involve 
decreasing the case load of midwives so that they have more time to devote to 
each patient.  Currently, Senegal does not meet the World Health Organization’s 
(WHO) standards for midwife/patient ratio, which results in long lines at health 
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centers, short patient/midwife interactions, and frustration both on the part of 
midwives and on the part of patients.  Midwife frustration manifests itself as 
rudeness and lack of respect towards patients who in turn feel intimidated.  
Several women from this sample stated that they refrained from asking health-
related questions to the midwives for fear of being humiliated.  One woman in the 
control group stated that she did not purchase any of the iron/folic acid tablets 
because she had lost her prescription shortly after her first prenatal visit and was 
fearful to return and ask for another one.  The current patient/midwife relation in 
health centers does not foster adequate counseling and in part explains why a 
large percentage of pregnant women do not return for follow-up prenatal visits at 
health centers.  This increases the risk of negative pregnancy outcomes not only 
because iron deficiency/anemia can be left undiagnosed and untreated but other 
pregnancy complications may not be detected.  Unfortunately, maternal and infant 
morbidity and mortality remain high in Senegal.   
 
3. Modifying the composition of the tablets that are currently available: WHO 
recommends that women receive daily supplementation of 60 mg of iron and 400 
µg folic acid.  The tablets that are available in Senegal only contain 250 µg folic 
acid.  Although folate status was not determined in this study, folate deficiency as 
a major cause of anemia has been documented in other countries in West Africa.  
Thus, supplementing women with the recommended dose of folic acid may 




Causes of anemia other than iron deficiency, malaria parasitemia, helminthes 
infection, and Hb S were not investigated in this study.  These potential causes include 
thalassemias, vitamins A, B12, and folate deficiencies.  A better understanding of the 
contribution of these factors to the risk of anemia can foster a more holistic approach to 
the treatment of anemia among pregnant women in Senegal. 
A second important contribution to the prevention and treatment of anemia would 
be an ethnographic research to uncover the beliefs and attitudes of women towards the 
causes of anemia and its prevention and treatment.  Cultural beliefs and traditional 
remedies have been largely dismissed by the public health community instead of being 
used to frame supplementation policies and programs.  Such ethnographic research 
should include key informants such as doctors, midwives, pharmacists, traditional healers 
(most people in Senegal have great faith in them and often seek both traditional and 
modern medicine), and of course the women themselves.  For example, a qualitative 
study in Nigeria showed that pregnant women did not perceive anemia and its symptoms 
as serious and therefore did not see the point of treating it.  Another study in Tanzania 
showed that women believed that anemia was caused by evil spirits who sucked pregnant 
women’s blood.  Even though the Tanzanian women recognized the symptoms of 
anemia, they did not take the iron tablets they were given, but instead turned to a 
traditional healer who promised to ward off the spirits with amulets and incantations.  
Such examples, illustrate the great need to gain a deep understanding of where iron/folic 
acid tablets fit in the tapestry of traditional medicines in Senegal and to use that 
understanding to make them acceptable to women. 
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Finally, a rigorous survey of the dietary iron intake of pregnant women is also 
needed.  In this study, we used a modified food frequency questionnaire which did show 
that women consumed iron absorption inhibitors frequently, but which did not allow us to 
relate dietary intake with hematological outcomes.  Such relationship could have only 
been established by collecting multiple diet records.  A better understanding of the 





 Appendix A: Food Frequency Questionnaire

















Beef          
Mutton          
Goat          




Heart (beef/mutton)          
Chicken          
Hen          
Turkey          
Fresh fish           
Dry fish          
Smoked fish           
Crustaceans           
Enrollment Date ____________________ (mm/dd/yyyy) 
[enrolld] 
 





Group Assignment ___________ 
[grpass] control = 1; treatment = 2 
 
Health Center ____________________ 
[hcid] Institute of Social Hygiene = 1; Philippe Senghor = 2; Roi 
Baudoin = 3; Center for Maternal and Infant Protection = 4; Gaspard 
Kamara = 5; Dominique = 6 
 


















Green beans          
Parsley          
Lentils          
Bissap          
Baobab leaf          
Groundnut          
















Orange (fruit/juice)          







Mango (fruit/juice)          
Papaya          
Fresh tomato           
Tomato paste          

















































Milk          
Milk curds          
Milk powder          
Yogurt          
Kew          
Eggs           
Coffee          
Tea          
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Appendix B : Socio-demographic questionnaire
1. Date of birth ________________ 
 [bdate] 
 
2. Age (years) __________ 
 [age] 
3. What is your ethnic group? [ethgrp] 
____ Wolof/Lebou (1) 
____ Poular (2) 
____ Serer (3) 
____ Mandingue/Soce/Malinke (4) 
____ Diola (5) 
____ Soninke/Sarakole (6) 
 
____ Bambara (7) 
____ Manjaak (8) 
____ Mancagne (9) 
____ Balant (10) 
____ Other (11) 
__________________________ 
4. What is your religion? [faith] 
____ Muslim (1) 
____ Christian (2) 
____ Animist (3) 
____ Other (4) 
 
____ No religion 
5. Years of formal education ________ 
 [educ] 
6. Can you read and write: [read] 
____ Easily (1) 
____ With difficulty (2) 
Enrollment Date ____________________ (mm/dd/yyyy) 
[enrolld] 
 





Group Assignment ___________ 
[grpass] control = 1; treatment = 2 
 
Health Center ____________________ 
[hcid] Institute of Social Hygiene = 1; Philippe Senghor = 2; Roi Baudoin 
= 3; Center for Maternal and Infant Protection = 4; Gaspard Kamara = 5; 
Dominique = 6 
 





Phone Number ___________________________ 
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____ Not at all (3) 
 
7. Are you employed? __________ 





9. Who is the head of your household? 
_______________________________ 




11. Marital status? [marital] 
____ Married (1) 
____ Separated (2) 
____ Divorced (3) 
____ Widowed (4) 
____ Single (5) 
 
12. Are you the only wife to your 
husband? 
[onlywife] (Y = 1; N = 2] 
_____________ 
13. Do you own your home? ______  
[ownhome] (Y = 1; N =2) 
 
14. If renting, how much rent do 
you pay per month? [morent] 
_________________ 
15. What source of water do you use for 
washing dishes, washing hands, and 
showering? [source1] 
____ Tap in the home (1) 
____ Public fountain (2) 
____ Delivery (3) 
____ Bottled (4) 
 
16. Do you use the same source for 
drinking water? [source2] 
________  
If not, which source do you use? 
____ Tap in the home (1) 
____ Public fountain (2) 
____ Delivery (3) 
____ Bottled (4) 
17. Type of toilets in the household? 
[toilet] 
____ Flush toilet (1) 
____ Private flush toilet (2) 
____ Cesspool/latrine (3) 
____ Other (4) 
____ No toilets (5) 
 
18. Do you possess the following? 
(Y = 1; N = 2) 
____ Radio [radio] 
____ Television [tv] 
____ Refrigerator/freezer [refer] 
____ VCR [vcr] 
____ Phone [phone] 
19. Do you have electricity? _________ 
[electr] (Y = 1; N = 2) 
 
20. How many rooms do you use 
for sleeping? [sleep] ____________ 
21. What material covers your floor? 
[material] 
____ Dirt/ Sand floor (1) 
____ Wood floor (2) 
____ Linoleum (3) 
____ Tile floor (4) 
____ Concrete floor (5) 
____ Carpet (6) 
22. Does someone in the household 
own the following? [hown] 
____ Bicycle (1) 
____ Motorcycle (2) 
____ Car (3) 
____ Horse-drawn cart (4) 
____ Other mode of transport (5) 
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____ Other (7) 
 
23. How is used water evacuated from 
your household? [waterdisp] 
____ City mains (1) 
____ Closed canal (2) 
____ Open canal (3) 
____ Septic tank (4) 
____ Street (5) 
____ Other (6) 
 
24. Where do you keep the 
household wastes? [waste] 
____ Trash bin with cover (1) 
____ Trash bin without cover (2) 
____ Plastic bag (3) 
____ Used kitchen utensils (4) 
____ Other (5) 
 
25. Where do you place the household 
waste pending disposal? [befdisp] 
____ Inside the household (1) 
____ Outside the household (2) 
26. How are the household wastes 
evacuated? [aftdisp] 
____ Pick up (1) 
____ Burial (2) 
____ Authorized depot (3) 
____ Unauthorized depot (4) 
____ Incineration (5) 
 
27. How much money do you spend on 




Appendix C: Pregnancy and health questionnaire
1. How many times have you been 
pregnant? [gravida] _________ 
 
2. How many children did you give 
birth to? [parity] _________ 
3. Did any children die? [childdie] (Y = 
1; N = 2) ________ 
 
4. If yes, how many? [nokiddie] 
_____ 
5. Age of your last child? 
______months 
[lastch]  
6. What medications are you currently 




7. Who gave you the medicines? 
[medsfrom] 
____ Medical doctor (1) 
____ Nurse (2) 
____ Midwife (3) 
____ Pharmacist (4) 
____ Friend/relative (5) 
____ Other (6) 
 
8. Have you been told that you have: 
[diseases] 
____ Diabetes (1) 
____ High blood pressure (2) 
____ Cancer (3) 
____ Kidney disease (4) 
____ Liver disease (5) 
____ HIV/AIDS (6) 
____ Other 
9. How would you describe your 
current state of health? [health]  
____ Excellent (1) 
____ Good (2) 
____ Fair (3)           ____ Poor (4) 
10. Have you received or donated 
blood in the last 2 months? 
__________ 
[blood] (Y =1; N =2) 
Enrollment Date ____________________ (mm/dd/yyyy) 
[enrolld] 
 





Group Assignment ___________ 
[grpass] control = 1; treatment = 2 
 
Health Center ____________________ 
[hcid] Institute of Social Hygiene = 1; Philippe Senghor = 2; Roi 
Baudoin = 3; Center for Maternal and Infant Protection = 4; Gaspard 
Kamara = 5; Dominique = 6 
 
Patient Number __________________ [hcno] 
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Present pregnancy prenatal record 
 
1.1st day of last period? ____________ 
[lmp] 
 
7. Stage of gestation 
___________ wks 
 
2. Weight? [ewt] _________ Kg 
 
8. Height? [ht] 
_____________ m 
3. Weight at follow-up? _______ Kg 
[fwt] 
 
4. Blood type? [bloodtyp] _________ 
 
9. RH factor? [rh] 
__________ 
5. Blood pressure?  




10. Serologic test for 
syphilis _________ 
[syphill] (negative = 1; 
positive = 2) 
 




Enrollment Date ____________________ (mm/dd/yyyy) 
[enrolld] 
 





Group Assignment ___________ 
[grpass] control = 1; treatment = 2 
 
Health Center ____________________ 
[hcid] Institute of Social Hygiene = 1; Philippe Senghor = 2; Roi 
Baudoin = 3; Center for Maternal and Infant Protection = 4; Gaspard 
Kamara = 5; Dominique = 6 
 
Patient Number __________________ [hcno] 
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Laboratory measurements at enrollment 
 
1.Hb ____________ g/L 
[ehb] 
 
2. EP _____________ µmol/mol 
heme 
[eep] 
3. SF ___________ µg/L 
[esf]  
 
4. Malaria ____________  
[malaria] (negative = 1; positive = 
2) 




5. CRP __________mg/L 
[crp] 
6. Intestinal Helminths________ 





#Eggs per gram of stool 
____________ 
[pdense] 
7. Hb variant______________ 
[Hbvar] 
 
Enrollment Date ____________________ (mm/dd/yyyy) 
[enrolld] 
 





Group Assignment ___________ 
[grpass] control = 1; treatment = 2 
 
Health Center ____________________ 
[hcid] Institute of Social Hygiene = 1; Philippe Senghor = 2; Roi 
Baudoin = 3; Center for Maternal and Infant Protection = 4; Gaspard 
Kamara = 5; Dominique = 6 
 
Patient Number __________________ [hcno] 
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Laboratory measurements at follow-up 
 
1.Hb ____________ g/L 
[hb2] 
 
2. EP _____________ 
µmol/mol heme 
[ep2] 
3. SF ___________ µg/L 
[sf2]  
 
Follow-up Date ____________________ (mm/dd/yyyy) 
[enrolld] 
 





Group Assignment ___________ 
[grpass] control = 1; treatment = 2 
 
Health Center ____________________ 
[hcid] Institute of Social Hygiene = 1; Philippe Senghor = 2; Roi 
Baudoin = 3; Center for Maternal and Infant Protection = 4; 
Gaspard Kamara = 5; Dominique = 6 
 





• The midwife prescribed/gave me iron/folic acid tablets: ____Yes; ____No 
• How many tablets have you taken/purchased since the last visit? ________ 
• How many tablets remain (count) ___________ 
 
Compliance:
If compliance is ≥70%: 
What influenced your decision to take the tablets as prescribed? 
 
If compliance is <70%: 
Why didn’t you take the tablets as prescribed?  
 
Follow-up Date ____________________ (mm/dd/yyyy) 
[enrolld] 
 





Group Assignment ___________ 
[grpass] control = 1; treatment = 2 
 
Health Center ____________________ 
[hcid] Institute of Social Hygiene = 1; Philippe Senghor = 2; 
Roi Baudoin = 3; Center for Maternal and Infant Protection = 4; 
Gaspard Kamara = 5; Dominique = 6 
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